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ABSTRACT OF DISSERTATION 
 
GLUCOCORTICOID-INDUCED CHONDROCYTE CYTOTOXICITY AT DOSES 
RECOMMENDED FOR INTRA-ARTICULAR THERAPY IN HORSES 
Intra-articular glucocorticoid injections are commonly used to treat synovitis 
and osteoarthritis in horses.  These agents are highly effective at relieving pain, 
swelling, and other symptoms of joint inflammation.  The drugs also have 
therapeutic benefits by down regulating the expression of cytokines and protease 
enzymes that participate in the degradation of articular cartilage.  However, 
detrimental effects on chondrocyte function and cell viability that is independent of 
osteoarthritis pathogenesis have been described and linked to glucocorticoid use.  
These side effects are both drug- and dose-dependent.  This study tested the 
hypothesis that manufacture recommended dosage levels of methylprednisolone, 
betamethasone, and triamcinolone that are widely used in equine clinical practice 
are cytotoxic to articular chondrocytes.  Drug-induced chondrocyte cytotoxicity was 
evaluated in monolayer cultures, cartilage explants, and equine fetlock joints.  Total 
RNA was isolated from control and IL-1β stimulated primary chondrocytes and 
synoviocytes in culture.  Changes in steady state mRNA for targeted gene transcripts 
related to inflammation and normal cell function were measured using reverse 
transcription and quantitative PCR.  Inducible nitric oxide synthase activity was 
evaluated using nitrite production.  Drug-induced chondrocyte cytotoxicity occurred 
at drug dosage levels frequently used in equine clinical practice. Both drug- and 
dose-dependent effects on chondrocyte and synoviocyte gene expression were 
observed.  Maximum anti-inflammatory activities for the glucocorticoids were 
observed at in vitro concentrations below manufacturer-recommended levels.    
Results from this study suggest that lower glucocorticoid dose ranges for intra-
articular therapy in horses should be validated to maximize the ratio of their 
therapeutically beneficial anti-inflammatory efficacy against detrimental effects on 
cell function and viability. 
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Chapter I Background and Literature Review 
I. Importance of Osteoarthritis: both in horses and humans
Osteoarthritis (OA), a degenerative joint disease, is the most common
muscuoskeletal disease both in humans and horses. Lameness due to joint injury 
and joint disease is the most prevalent cause of diminished function and poor 
performance in racehorses. Several epidemiologic studies have documented the 
substantial impact of joint disease. Thirty-six to fifty-two percent of racehorses up 
to four years old have clinical sign of lameness (Jeffcott et al., 1982, Rossdale et al., 
1985). According to a study done at Cornell University between 1983 and 1990 on 
equine patient admissions, 42% of racehorses older than 24 months with lameness 
had clinical sign of OA (Fubini et al., 1999).  Likewise, OA not only affects racehorses, 
but also non-racing horses. A survey suggested that 60% of non-racing horses older 
than 24 months with lameness had clinical sign of OA (Caron et al., 2003).  
Osteoarthritis is also recognized as a major concern in human health, because of a 
large number of people involved and its severe impact on quality of life. It affects 
about 60% of men and 70% of women over the age of 65 (Sarzi-Puttini et al., 2005). 
It is a common cause of long-term disability in many populations of middle aged and 
older people (Praemer et al., 1999; Felson et al., 1995).  Approximately 40% of 
adults over 70 suffer from OA of the knee, 80% of people with OA have limitations in 
movement, and about 25% cannot perform daily living activities (World Health 
Organization and bone and joint decade, 2001).Osteoarthritis has significant health 
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and quality of life implications for individuals, societies, and economies around the 
world – problems that are expected to get even worse as with aging populations 
(Brooks et al., 2002).  
 
Osteoarthritis is first and foremost characterized by the ongoing destruction of 
articular cartilage in diarthrodial joints.  Although it may develop in any joint, areas 
most commonly affected are weight bearing joints of the legs, including knees, and 
hips in humans, or stifle, carpus, and fetlock joints in horses. Osteoarthritis may 
result from injury, an abnormal growth pattern, or inherited factors.  Mechanical 
impact is recognized as an important parameter for all of these issues (Brandt et al., 
2009), and may also limit intrinsic joint repair mechanisms attempting to restore 
joint function.  Due to years of mechanical stress, cartilage extracellular matrix 
components, which are responsible for the biomechanical properties of the tissue, 
are broken down and the normal balance between their synthesis and degradation 
is lost.  Over time, the structural integrity of articular cartilage fails and joint 
movement becomes increasingly painful and restricted. 
 
II. Joint Inflammation in Osteoarthritis 
Osteoarthritis is characterized by changes in composition, structure and function 
of the articular cartilage. Although articular cartilage degeneration followed by 
erosion is the main identifying characteristic of OA, recent evidence supports a 
newer perspective that OA is a whole joint disorder affecting all joint tissues 
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including all connective tissues within and around the joints. OA results from joint 
degeneration, a process that includes degradation of the articular cartilage 
accompanied by attempted repair of articular cartilage, thickening of the 
subchondral bone, formation of subchondral bone cysts and osteophytes, and 
variable degrees of inflammation of the synovium (Buckwalter et al., 1995, 1997, 
2000, Gerwin et al., 2004) (Figure 1). These changes usually limit joint movement 
and typically cause pain. Pain is the most common appearance of OA and the major 
cause of lameness associated with the disease. It can be generated by two types of 
factors: mechanical stimuli and inflammation. Mechanical stimulation may elicit 
inflammation response through tissue injury (Rene et al., 2010). OA is a process of 
changes of joint tissues responding to inflammatory mediators within the affected 
joint. It is frequently associated with signs and symptoms of inflammation, such as 
joint pain and swelling, leading to significant functional impairment and disability 
(Felson et al., 2006). Inflammation, that occurs in response to mechanical irritation 
and injury is central to the pathogenesis of OA and involves not only chondrocytes, 
but also cells in the synovial membrane and subchondral bone. Inflammatory 
cytokines, chemokines, and other inflammatory mediators, produced by the 
synoviocytes and chondrocytes, can be measured in the synovial fluids of 
osteoarthritis patients (Rainbow et al., 2012).  
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Figure 1.  Healthy and osteoarthritic joints (Adopted from: N. Gerwin, 2006). 
 
The role of synovial membrane in joint inflammation 
Osteoarthritis research is traditionally focused on the understanding of changes 
on articular cartilage integrity and chondrocyte pathobiology.  The synovial 
membrane changes are largely neglected. However, synovial membrane is an 
important portion of the joint and synovial inflammation is an important component 
of OA, contributing to the imbalance of chondrocyte catabolic and anabolic activities 
(Loeser et al., 2006). 
The synovial membrane is a vascular connective tissue that lines the 
noncartilaginous surfaces within a joint cavity (Blom et al., 2007, Radin et al., 2001). 
The synovial lining cells consist of two different cell types: type A and type B 
synoviocytes. The two cell types execute different functions. Type A synoviocytes 
are macrophage-like cells that can eliminate excess materials and potential 
pathogens from the joint (Iwanaga et al., 2000; Blom et al., 2007). Type B 
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synoviocytes are fibroblast –like cells that are responsible for producing hyaluronan 
(HA) which is the main component of synovial fluid. In a normal joint, these two 
type of synoviocytes function together to maintain a healthy environment. However, 
in pathologic conditions, type A synoviocytes can stimulate type B synoviocytes to 
produce inflammatory mediators and matrix degrading enzymes.   
Articular cartilage relies on adjacent tissues, such as subchondral bone and 
synovial membrane, to help maintain the health of the chondrocytes. The synovial 
membrane regulates molecules moving into and out of the joint space and maintains 
the composition of synovial fluid (Scanzello et al., 2012). Synovial fluid not only is 
important for reducing friction of joint movement, but also functions to transport 
nutrients and oxygen to the cartilage (Blom et al., 2007; Hui et al., 2011). However, 
the permeability of the synovial membrane can be altered when inflammation 
occurs. This likely contributes to the decreased concentration of HA and lubricin in 
synovial fluid. The level of HA has been reported to be elevated in concentration 
during inflammation, and serum HA concentrations have been used as a marker of 
synovitis (Goldberg et al., 1991). 
Synovial inflammation is common in both early- and late-stage OA, although 
they are generally of lower grade than those observed in rheumatoid arthritis (RA) 
(Sellam et al., 2010). Moderate or marked inflammatory synovitis is present in 
nearly 50% of the synovial membranes from patients with OA (Goldenberg et al., 
1982; Pearle et a. 2007). This condition is marked by dramatically increased 
secretion of pro-inflammatory cytokines and proteolytic enzymes from synoviocytes 
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(Fernandes et al., 2002; Goldring et al., 2007; Revell et al., 1988; Ashraf et al., 2011; 
Bondeson et al., 2010). Pro-inflammatory cytokines, including interleukin 1β (IL-1β), 
interleukin 6, and tumor necrosis factor-α (TNF-α), are reported to mediate the 
cartilage degeneration and joint pain associated with OA (Sellam et al., 2010; 
Wassilew et al., 2010). The most extensively studied cytokines are IL-1β and TNF-α, 
which can induce expression of matrix degrading proteases, suppress matrix 
synthesis and promote cartilage catabolism (Aigner et al., 2006; Goldrin et al. 2009). 
Matrix metalloproteinases (MMPs), including MMP-1, MMP-3, and MMP-13, can be 
detected in OA synovial fluid samples, although at significantly lower levels than in 
RA joints (Pozgan et al., 2010).  
Articular cartilage in osteoarthritis 
Articular cartilage is a highly specialized, avascular, and aneural connective 
tissue that forms the smooth gliding surface of the diarthrodial joints (Figure 2). 
Cartilage allows the frictionless motion of the joint, in which it absorbs and 
dissipates loading stress. It is largely an extracellular matrix (ECM), which is 
synthesized by sparsely distributed resident cells, named chondrocytes. ECM is 
composed mainly of a high concentration of proteoglycans (aggrecan), collagen 
fibers, non-collagenous non-proteoglycaneous proteins, and a large amount of water 
(Heinegard et al., 1992). The integrity of articular cartilage is altered to some degree 
in all joints with OA (Figure 3). Cartilage matrix components are broken down and 
normal balance of synthesis and degradation is lost. A net loss of proteoglycan 
content is one of the hallmarks of all stages of osteoarthritic cartilage degeneration 
(Figure 3) (Mankin et  al., 1971). 
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Figure 2. Diarthrodial joint (A, adopted from www.studyblue.com) and structure of 
articular cartilage (B, adopted from php.med.unsw.edu.au). 
 
  
Figure 3. Cartilage in healthy and osteoarthritic joints. The normal cartilage has 
smooth articular surface (A) and OA cartilage shows fissuring of articular surface 
(B).  Proteoglycans abundant in cartilage matrix was stained with red color using 
Safranin-o. Histological appearance of healthy articular cartilage showed a good 
Safranin-o staining. Safranin-o stain was decreased in OA cartilage. 
A B 
A B 
 
 
8 
 
 
 
Chondrocytes, the only cell type in articular cartilage, are responsible for the 
balanced turnover of the ECM and maintenance of structural integrity in 
cartilaginous tissues (Aigner et al., 2006). During the osteoarthritic disease process, 
cellular reaction patterns of chondrocytes are changed. It can respond to joint injury 
or biomechanical perturbation by undergoing cell death, proliferation, or 
phenotypic modulation. Compared to normal cartilage, chondrocytes alter their 
gene expression profile in OA (Aigner et al., 2001). It is largely reported that 
chondrocytes have the capacity to up-regulate synthetic activity or increase the 
production of inflammatory mediators and matrix degradation enzymes, which are 
also produced by other joint tissues (Goldring et al., 2009). Chondrocytes obtained 
from OA tissues actively express MMPs, IL-1β, TNF-α, IL-6, IL-8, and a number of 
other genes that enhance or modulate inflammatory and catabolic responses, 
inducible nitric oxide synthase(iNOS) and cyclooxygenase 2 (COX-2) (Loester et a., 
2012; Pelletier et al., 2001). These molecules act within cartilage in an autocrine or 
paracrine manner to promote a catabolic state, which leads to progressive cartilage 
degradation in OA joints (Attur et al., 1998). Chondrocytes also produce a large 
amount of NO when stimulated by IL-1β and TNF-α. NO inhibits the synthesis of 
extracellular matrix components such as type II collagen and proteoglycans, but 
increases activity of MMPs (Aigner et al., 2002). 
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Pro-inflammtory cytokines and matrix metalloprotease 
It is believed that different inflammatory molecules in the development of OA 
play an important role. IL-1β and TNF-α produced by activated synoviocytes, 
mononuclear cells or by chondrocytes are the 2 major cytokines in the pathogenesis 
of OA (Fernandes et al., 2002). IL-1β is primarily synthesized as a precursor and 
released in the active form (Mosley et al., 1987). The catabolic effects of IL-1β are 
multiple. It not only can stimulate its own production, induce the expression of 
MMPs and other catabolic genes, but also inhibit the synthesis of matrix 
constituents such as collagens and proteoglycans (Pelletier et al., 2008). This 
cytokine also plays important roles in normal joints, including stimulation of the 
turnover of extracellular matrix (Pelletier et al., 2008). Although TNF-α has only 
been detected in OA articular tissue at low levels, it also appears to be an important 
mediator of cartilage matrix degradation and a pivotal cytokine in inducing synovial 
membrane inflammation (Fernandes et al., 2002). IL-1 and TNF- α can stimulate the 
mitogen-activated protein kinase (MAPK) pathways and nuclear factor κB (NF-κB) 
pathway which are central inflammatory pathways in OA (Saklatvala et al., 2007). 
These kinase cascades lead to the expression of many inflammatory genes and MMP 
genes which facilitate the degradation of several ECM proteins, such as collagens, 
proteoglycans, fibronectin, link protein and other matrix proteins which are critical 
for normal cartilage function and integrity (Malemud et al., 2004).  
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The matrix degrading enzymes found in the OA joint include aggrecanases and 
collagenases, which are members of the MMP family. These include stromelysin-1 
(MMP-3), collagenase -1(MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), 
and aggrecanases (Clark et al., 1998; Woessner et al., 1991). These proteinases are 
very much involved in the cartilage matrix degradation in OA (Poole et al., 1995).  
Cartilage matrix degradation in early OA may be due to aggrecanase and MMP-3, 
which degrade aggrecan. Then increased activity of MMP-13 is highly efficient at 
degrading type II collagen (Dahlberg et al., 2000). Once the collagen network is 
degraded, the damage to the cartilage structure cannot be reversed. 
The main objectives in the management of OA are to reduce symptoms, 
minimize functional disability, and limit progression of the structural changes. 
Therefore, controlling joint inflammation and immediate damage to cartilage, as 
well as minimizing long-term degenerative structure changes, are important 
objectives of OA therapy. 
 
III. Anti-inflammatory therapies commonly used for synovitis and 
osteoarthritis 
There are a number of treatments available for synovitis and osteoarthritis. 
Aims of these treatments are to relieve the pain, prevent the cytokines and matrix 
degrading enzymes from compromising the articular cartilage, and finally return the 
joint to normal as quickly as possible. Non-pharmacological therapies and medical 
treatments are discussed in this section. 
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Non-pharmacological therapies to reduce inflammation 
Non-pharmacological therapies can be used as the first step, both in humans 
and horses, for joint injury and disease treatment (Roos et al., 2012). These 
treatments can be used alone or in combination with medical and surgical 
treatments (Figure 4).  
Surgery
Pharmacological therapies
Education, exercise and weight control
Few
Some
All
 
Figure 4. The osteoarthritis treatment pyramid. Non-pharmacological treatments 
can be used for all patients. Pharmacological therapies are useful for some of the 
patients. Few patients need to have the surgery to maintain the joint function. 
 
Physical therapy and rehabilitation are commonly used non-pharmacological 
treatments for horse synovitis and osteoarthritis. Cold hydrotherapy might be 
extremely useful as a primary treatment immediately after an acute joint injury. It is 
indicated to retard the inflammatory processes and reduce edema (Hickman J, 
1964). After 48 hours, hot hydrotherapy might help to relieve pain and reduce 
tension in inflamed tissues (Adams OR, 1974; Lehmann JF et al., 1982; Michlovitz SL 
 
 
12 
et al., 1996; Prentice WF et al., 1994). Swimming is the closest treatment to non-
weight bearing motion, which is practiced in human sports medicine and in horse 
sport medicine (McIlwraith et al., 2001).  It is used in the convalescent period with 
joint injury to maintain the horse’s condition while relieving joint trauma.  
Recently, there also has been considerable use of treatments such as 
electromagnetic therapy, electrostimulation, and low level laser for various 
musculoskeletal conditions including traumatic joint disease. The value of 
extracorporeal shock save therapy (ESWT) has been demonstrated with 
experimental osteoarthritis in the horse (Frisbie et a., 2009).  It significantly 
reduced the degree of lameness in horses, although no disease-modifying effects 
were evident (Frisbie et a., 2009). The effects of non-surgical defocalized carbon 
dioxide laser therapy (DLT) on acute synovitis and capsulitis was evaluated 
(Lindholm et al., 2002). Although no control was established, observer-blind and 
prospective studies still observed beneficial effects of DLT on reducing the degree of 
lameness, which was comparable with conventional intra-articular medical 
treatments (Lindholm et al., 2002). 
 
Current commonly used anti-inflammatory drug therapy  
Drug therapy is one of the most utilized treatments for OA in equine practice.  
Evaluating therapeutic efficacy has largely focused on improvements in pain 
management and joint function. The mainstay of medical treatment has included 
systemic non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular (IA) 
corticosteroids, viscosupplementation, and chondroprotectants (Goodrich et al., 
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2006). The following section discusses systemic medical treatment of OA, followed 
by IA and other topical therapies. 
Systemic treatment of OA 
NSAIDs are by far the most commonly used drugs in this category. The effect of 
NSAID is primarily the inhibition of cyclooxygenase (COX) enzymes in the 
arachidonic acid cascade, thus inhibiting prostaglandins production (Higgins et al., 
1984).  There are two forms of cyclooxygenase: constitutive COX 1 and inducible 
COX 2.  It is reported that COX 2 enzyme may be primarily responsible for 
inflammatory response and COX 1 is responsible for producing prostaglandins 
involved in regulating normal cellular processes, such as protection of mucosal 
barriers in the gastrointestinal tract (Meade et al., 1993).  The identification of COX 
1 and COX 2 may explain, the variability of efficacy, as well as toxicity, of different 
NSAIDs. Most of the older NSAIDs have been shown to inhibit both COX 1 and COX 2. 
Moreover, some of them, such as aspirin, indomethacin and piroxicam, are reported 
to be more potent inhibitors of COX 1 than COX 2, which means that they more 
negatively affect normal physiological function than beneficially inhibit 
inflammation (May et al., 1996). Selective COX 2 inhibitors have been developed and 
demonstrated a superior gastrointestinal safety profile in humans, while providing 
comparable anti-inflammatory potency (Chen et al., 2008). However, selective COX 
2 inhibitors are known to cause cardiovascular (CV) events (McGettigan et al., 2006), 
and its gastrointestinal protective benefits may be negated if the patient is also 
taking aspirin (Chan et al., 2007). Selective COX 2 inhibitors have also become 
available for the treatment of OA in horses, but traditional nonselective NSAIDs are 
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still routinely used. Table 1 summarizes dosages and ways of administration for the 
most commonly used NSAIDs in horses. 
  
 
Name of Drug Route of Application 
Phenylbutazone Oral 
Flunixin Oral or IV 
Carprofen Oral or IV 
Ketoprofen IV or IM 
Vedaprofen Oral 
Meloxicam  Oral 
Naproxen Oral or IV 
 
Table 1. Overview of the most commonly used NSAIDs with their route of 
administration. 
 
Other systemic treatments for OA in horses include intramuscular (IM) 
polysulfated glycosaminoglycans (PSGAG), IV or oral sodium hyaluronate (HA), and 
neutraceuticals.  PSGAGs alter OA progression by sustaining or promoting 
chondrocyte metabolic activity and inhibiting the detrimental effects of cytokines or 
prostaglandins on cartilage.  HA has anti-inflammatory effects in the joint. Horses 
treated with HA have reduced lameness, better synovial membrane scores, and a 
reduction in prostaglandins in joints compared to joints of horses receiving saline 
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(Goodrich et al., 2006).  Neutraceuticals are used to treat horses suffering from OA 
or other chronic joint disorders and in most cases contain mixtures of chondroitin 
sulfate and glucosamine.  These compounds are supposed to have a disease-
modifying effect. There has been controversy about the potential usefulness of these 
compounds in horses since these products are not FDA controlled (Goodrich et al., 
2006). 
Local treatment of OA  
Intra-articular glucocorticoids are commonly used and can be extremely 
effective for the therapeutic management of OA symptoms. Glucocorticoids are 
powerful anti-inflammatory agents that strongly suppress the immune response.  
However, glucocorticoid use became controversial because of side effects, 
particularly on steroid-induced deterioration of articular cartilage, which also 
known as steroid arthropathy. There now seems to be common agreement that if 
used judiciously, intra-articular glucocorticoid therapy can be extremely beneficial. 
Mechanism of glucocorticoids, side effects, and type of corticosteroid used are 
discussed in detail in the following section.   
Hyaluronic acid (HA), also called hyaluronan, is a large nonsulphated 
glucosaminoglycan and synthesized by fibroblast-like synoviocytes of the synovial 
membrane (Howard et al., 1996).  It is an important component of the joint fluid and 
serves various functions, such as viscoelasticity of the synovial fluid and boundary 
lubrication of the articular cartilage (Scanzello et al., 2012). HA is also an important 
component in articular cartilage matrix and can be locally produced by 
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chondrocytes. It has been extensively used as intra-articular treatment in horses as 
viscosupplementation and anti-inflammatory agent (Goodrich et al., 2006). The 
combination of intra-articular glucocorticoids and HA is popular in equine practice, 
as it may permit the reduction of the dose of glucocorticoids and may counteract the 
possible deleterious effects of these drugs on the cartilage (Caron et al. 2005).  
 
IV. Intra-articular glucocorticoids: mechanisms of action and side effects 
     As noted above, glucocorticoids are potent anti-inflammatory agents widely used 
in therapeutic applications for osteoarthritis (Todhunter et al. 1998, Goodrich et al. 
2006 and Stitik et al. 2006). Glucocorticoids exert their effects by binding to 
glucocorticoid receptors (GR) localized in the cytoplasm of target cells. Central to 
the action of glucocorticoids is the interaction of glucocorticoid molecules with the 
cytoplasmic glucocorticoid receptor, in response to which a vast number of 
intracellular events are entrained. The efficacy of glucocorticoids in alleviating 
inflammatory disorders results from the pleiotropic effects of the glucocorticoid 
receptor on multiple signaling pathways (Adcock et al. 2000, Smoak et al. 2004, and 
De Bosscher et al. 2003). Within the cell, glucocorticoid acts in three ways:  direct 
and indirect genomic effects and nongenomic mechanisms (Buttgereit et al 1998 
and Rhen et al. 2005). First, the glucocorticoid receptor complex moves to the 
nucleus, and binds as a homodimer to DNA sequences called glucocorticoid-
responsive elements (GRE) or negative glucocrticoid-responsive elements (nGRE) 
(Smoak et al, 2004 and Rhen et al. 2005), thereby facilitating or inhibiting 
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transcription (Figure 5). This process is highly dynamic and has demonstrated to 
increase the synthesis of certain anti-inflammatory proteins, including lilpocortin-1, 
IL-1 receptor antagonist, and IL-10, but is also related to glucocorticoid-induced 
side effects (Smoak et al, 2004 and Rhen et al. 2005). Second, glucocorticoid 
receptor sequesters and interacts with other transcription factors, such as nuclear 
factor-kappa B (NF-kB) and activator protein-1 (AP-1), to suppress transcription 
(Figure 5). The third mechanism is called non-genomic actions, which are mediated 
through membrane-associated receptors and second messengers (Buttgereit et al 
1998).  
Although these medications effectively decrease inflammation, side effects 
independent of OA pathogenesis have been identified (Fubini et al. 2001). Cartilage 
collected from joints treated with glucocorticoids have pathological changes that 
include chondrocyte cell death, reduced proteoglycan content and rate of synthesis, 
decreased collagen synthesis, and an increase in the percentage of water 
(Chunekamrai et al. 1989, Richardson et al. 2003). Over time, these changes 
compromise the structural integrity and biomechanical properties of articular 
cartilage.   In regards to bone metabolism, glucocorticoids have been found to 
inhibit osteoblasts which function in bone production and increase osteoclast 
activity which aid in bone resorption, thereby creating a bone that is more 
susceptible to the development of osteoporosis or fractures.  Another side effect of 
glucocorticoids includes avascular necrosis and altered bone repair (Bitto et al, 
2009).  The effects of glucocorticoids on bone metabolism and structure has been 
extensively studied in humans and lab animals, but not in horses.  The therapeutic 
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use of glucocorticoids for OA is limited by these side effects, especially during long-
term treatment. 
Methylprednisolone acetate (MPA), betamethasone, and triamcinolone are 
three commonly used intra-articular corticosteroids in horses (Caron et al. 2005).  
Although these drugs have strong anti-inflammatory activities, some detrimental 
effects have been reported. Many studies have been conducted to observe the 
beneficial and side effects of MPA on cartilage, subchondral bone, and synovium. 
Side effects were reported both in vivo and in vitro studies (Frisbie et al. 1998, 
MacLeod et al. 1998, Shoemaker et al. 1992). It appears that lower doses inhibit 
inflammation while maintaining the normal joint metabolism (Todhunter et al. 
1996).  Further studies are needed to accurately identify the best MPA dose in the 
horse.  A study looked at one dose of MPA (100 mg administered in the middle 
carpal joint) and found no significant side effects on subchondral bone, but indicated 
further research with multiple drug compounds at varying doses need to be 
examined to draw conclusions regarding glucocorticoid effects on bone structure 
and metabolism  in the equine (Murray et al, 2002).  There is no significant 
detrimental effect observed in the cartilage following administration of 
betamethasone in horse joints (Foland et al. 1994). However, side effects like 
suppression of proteoglycan synthesis are detected with in vitro work (Frean et al. 
2002). Triamcinolone was reported to inhibit the inflammatory molecules without 
side effects on cartilage extracellular matrix (Celeste et al. 2005, Dechant et al. 2003, 
Frisbie et al. 1997, Kawcak et al. 1998). According to the above finding, the specific 
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type of glucocorticoid used and the concentration achieved following administration 
plays an important role on side effects of these drugs on cartilage.  
 
 
Figure 5. Mechanisms of transactivation and transrepression actions of 
glucocorticoids and glucocorticoid receptor in the cell. 
      
 
V. New anti-inflammatory pharmacologic agents: dissociative 
glucocorticoids 
As previously mentioned, the genomic action of glucocorticoids can be divided 
into two processes: transactivation and transrepression.  It is widely accepted that 
the numerous desirable anti-inflammatory and immunomodulating effects of 
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glucocorticoids are mediated by their transrepression properties (Lin et al., 2002), 
whereas most of the adverse side effects are mediated through transactivation 
mechanisms (Schacke et al., 2002).  Significant side effects of glucocorticoids lead to 
the development of several new compounds.  Dissociative glucocorticoids, a novel 
group of glucocorticoid ligands, bind selectively to the glucocorticoid receptor and 
differentially recruit downstream cofactors (Catley et al. 2007).  These compounds 
cause a receptor conformation that prefers monomer glucocorticoid receptor and 
protein interaction rather than homodimer glucocorticoid receptor DNA binding 
(Stahn et al., 2007).  As a consequence, they can inhibit the activity of MAPK and NF-
κB pathways by protein-protein interaction like glucocorticoids, while having fewer 
side effects than glucocorticoids (Cogylan et al. 2003, Humphrey et al. 2006, and 
Owen et al. 2007).  Some dissociative glucocorticoids have a similar level of anti-
inflammatory activity compared to prednisolone, both in vitro and in vivo (Cogylan 
et al. 2003, Humphrey et al. 2006, and Owen et al. 2007). This list of potential 
alternative compounds tested in various in vitro and in vivo studies are provided in 
Table 2. 
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Drug In vitro 
testing 
In vivo animal model 
testing 
Human clinical trial 
Dissociative Non-steroidal Compounds 
AL-438 ✓ ✓ NT 
LGD-5552 ✓ ✓ NT 
ZK 216348 ✓ ✓ Phase II (Atopic Dermatitis) 
Compound A ✓ ✓ NT 
PF-803 ✓ ✓ Phase II (rheumatoid 
arthritis) 
Dissociative Steroidal Compounds 
RU-
Compounds 
✓ ✓ NT 
VBP1 ✓ ✓ NT 
VBP15  ✓ ✓ Phase I (Duchenne muscular 
dystrophy 
 
Table 2. Potential alternative therapeutic dissociative compounds for treating 
inflammatory diseases. “✓” means has already been completed. “NT” stands for not 
tested. 
 
Dissociative non-steroidal compounds 
AL-438 (Coghlan et al., 2003; Elmore et al., 2001) and LGD-5552 (Miner et al., 
2007; Lopez et al., 2008) are nonsteroidal glucocorticoid receptor ligands which 
bind the glucocorticoid receptor with specificity and relatively high affinity.  In vitro 
experiments indicate that AL-438 and LGD-5552 both effectively repress the 
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production of TNF-α or IL-1β induced IL-6 and E-selectin levels similar to steroids 
(Coghlan et al., 2003; Elmore et al., 2001; Miner et al., 2007; Lopez et al., 2008). 
These two compounds were also tested in rat models showing desirable anti-
inflammatory effects and a promising lack of adverse effects, such as without 
affecting glucose or bone metabolism (Coghlan et al., 2003; Elmore et al., 2001; 
Miner et al., 2007; Lopez et al., 2008). 
Compound A (Bosscher et al., 2005; Dewint et al., 2008) and ZK216348 
(Schacke et al., 2004) are also non-steroidal glucocorticoid receptor ligands which 
demonstrated anti-inflammatory effects with reduced detrimental side effects both 
in vitro and in vivo.  
Dissociative steroidal compounds 
The first dissociative steroidal compounds were discovered by Roussel-Uclaf 
(RU), including a series of RU-steroidal compounds.  These RU compounds were 
determined to retain transrepression action with weakly transactivation properties 
in vitro but not in vivo (Belvisi et al., 2001; Schacke et al., 2007; Chen 2008). 
In recent years, an increasing number of dissociative glucocorticoids have been 
described. A very interesting substance is, for example, VBP1 and VBP15 
(anecortave desacetate) (Baudy et al., 2012).  VBPs are Lazaroid ∆-9,11 analogs, 
which were developed originally as nonglucocorticoid steroids with effects on cell 
membranes and tested clinically for neuroprotection by the inhibition of lipid 
peroxidation (Taylor et al., 1996; Bracken et al., 1997; Kavanagh and Kam, 2001). 
Lazaroids have been reported to inhibit acute inflammation through the 
 
 
23 
suppression of inducible nitric oxide synthase (iNOS) (Altavilla et al., 1999), TNF-α 
(Altavilla et al., 1998), and NF-kB (Fukuma et al., 1999).  In the recent study by 
Baudy et al (2012), VBP1 and VBP15 were tested for anti-inflammatory efficacy and 
side effects both in vitro and in vivo. The results showed potent inhibition of TNF-α 
induced NF-kB signaling in cell reporter assays, and a reduction of muscle 
inflammation and improvements in multiple muscle function assays in two mouse 
models of muscular dystrophy.  Meanwhile, VBP15 exhibited lower affinity for 
mineralcorticoid receptor than the other VBPs and maintained comparable anti-
inflammatory efficacy to prednisolone (Heier et al. 2013). Accordingly, VBP15 
shows promise as a potentially safer therapeutic agent for chronic inflammatory 
disorders. Currently, VBP15 is undergoing the Phase I clinical trial. 
VI. Articular chondrocyte culture 
Primary articular chondrocytes and cell lines 
Chondrocyte culture experiments are widely used for investigating the 
intracellular and molecular events associated with chondrocyte biological function 
and activation. Several culture models have been proved useful for studying 
chondrocyte function, such as primary cultures of animal or human chondrocytes, 
and cell lines from chondrosarcoma.  However, chondrocyte cell lines cannot be 
entirely substituted for primary cultures, as major cell biology differences have been 
shown between normal and transformed chondrocytes (Mallein-Gerin et al. 1993, 
Stokes et al. 2001).  
 
 
24 
Primary articular chondrocyte culture methods 
Many in vitro culture methods have been developed for the investigation of 
chondrocyte and cartilage biological properties, including monolayer cultures, 
several forms of three-dimensional (3D) aggregate cultures systems, and cartilage 
explants models (Adolphe et al., 1992; Tew et al., 2008).  Monolayer culture is a 
commonly used in vitro method to grow chondrocytes and generate sufficient cell 
numbers for experimental analyses.  However, chondrocytes cultured using this 
approach may undergo a characteristic process of cellular dedifferentiation, marked 
by a decrease in type II collagen synthesis and aggrecan core protein expression and 
the induction of type I collagen expression (Darling et al., 2005; Goessler et al., 2004; 
Goessler et al., 2005).  This phenomenon is influenced to some extent by seeding 
density and is accelerated by growth in medium supplemented with serum and by 
passage (Hering et al., 1994; Ronziere et al., 1997; Matmati et al., 2012).  Three-
dimensional aggregate cultures systems, which include nonadherent aggregates, 
pellets, and cells embedded in an artificial material made of alginate, agarose, or 
collagens (Thirion et al., 2004), maintain their differentiated phenotype better than 
that of monolayer cultures.  However, cell proliferation is limited so that large 
numbers of primary cells are needed for each experiment. In addition, extracting the 
cells from the artificial matrix can be technically challenging (Thirion et al., 2004).  
Experiments designed using a combination of chondrocyte culture methods, 
supported by in vivo studies where possible, facilitates biological discovery. 
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VII. Knowledge gaps, hypothesis, and specific aims. 
Many important knowledge gaps remain, both with regard to OA pathogenesis 
and treatment.  For equine patients, basic questions such as the optimal use of 
established medical therapies continue to be debated.  Even with the extensive use 
of intraarticular corticosteroids on equine patients, objective data on dose-
dependent relationships between anti-inflammatory efficacy and chondrocyte 
toxicity are limited.  The objective of this dissertation was to evaluate these 
relationships for three commercial glucocorticoids that are widely used in clinical 
settings for the management of equine synovial joint inflammation. The hypothesis 
tested was that methylprednisolone, betamethasone, and triamcinolone that are 
widely used in equine clinical practice are cytotoxic to articular chondrocytes.  
Dose-dependent anti-inflammatory profiles of methylprednisolone, betamethasone, 
and triamcinolone in articular chondrocytes and synoviocytes were defined and 
compared.  Glucocorticoid-induced chondrocyte cytotoxicity in monolayer culture, 
articular cartilage explants, and in vivo was evaluated. 
 
Copyright ©  Wenying Zhu 2015 
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Chapter II Materials and Methods 
I. Cell isolation and culture  
Equine articular chondrocytes and explants 
1. Articular cartilage collection and chondrocyte cell isolation 
Full-thickness articular cartilage was harvested immediately postmortem from 
normal synovial joints of adult horses. For each horse, chondrocytes were 
enzymatically isolated from the cartilage matrix and cryopreserved as described 
previously (Nixon et al., 1992; Stewart et al., 1998). Articular cartilage was minced 
with a scalpel and digested overnight in basal digestion medium [OPTI-MEM, 5% 
fetal bovine serum, 1% L-glutamine, 25 μg/mL L-ascorbic acid phosphate (Wako 
Chemicals USA, Richmond, VA), 50 U/mL penicillin, and 50 μg/mL streptomycin)], 
and 0.75% collagenase II (Worthington Biochemicals,Freehold, NJ).  After digestion, 
the cell suspension was filtered through a sterile funnel containing a base layer of 
44µm mesh (Nylon membrane, Millipore, NY) and 4 layers of cheesecloth into 50 ml 
conical tubes.  The isolated chondrocytes were rinsed with PBS solution and 
counted.  Cell viability was assessed using trypan blue staining with an automated 
(ViCell, Beckman Coulter) analyzer.  An experiment was continued only when the 
proportion of viable cells was > 95%.  
2. Chondrocyte monolayer culture 
Monolayer chondrocyte cultures were established at a seeding density of 0.4 x 
106 cells/well in 6-well plates and cultured for 5 days in Opti-MEM (Gibco, 11058-
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021) with 5% fetal bovine serum, 1% L-glutamine, 25 µg/ml L-ascorbic acid 
phosphate, 50 U/ml penicillin and 50 µg/ml streptomycin.  On day 6, the confluent 
cultures were washed twice with serum-free Opti-MEM medium, followed by 
culturing in Opti-MEM medium without serum for another 5 days.  Various 
experiments were started on day 11.  Chondrocytes used to assess glucocorticoids-
induced cytotoxicity were seeded in 96 well plates at a density of 1 x 104 cells/well 
and cultured in the same Opti-MEM with 5% fetal bovine serum for 24 hours.  
Medium was changed every 2-3 days. 
3. Chondrocyte aggregate culture 
Nonadherent aggregate cultures were maintained in hydrogel-coated 6-well 
plates to prevent cell adhesion and maintain cartilage phenotype.  Three million 
cells were placed in each well in 5 ml of medium and cultured at 37 oC with 5% 
carbon dioxide at saturated humidity in Opti-MEM serum free medium, 
supplemented with 1% L-glutamine, 25 µg/ml L-ascorbic acid phosphate, 50 U/ml 
penicillin and 50 µg/ml streptomycin.  During the first 72 h of culture, the floating 
cells spontaneously came together to form clearly visible aggregates.  At each 
medium change, spent medium was aspirated and centrifuged at 300 rcf for 5 
minutes. Aspirated cells were resuspended in 5 ml of fresh medium and returned to 
the appropriate wells. Various experiments were started on day 11.   
4. Cartilage explants culture 
Articular cartilage was aseptically collected as full-thickness explants from 
normal synovial joints of adult horses between the age of 3 and 4 years.  A 6-mm 
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diameter biopy punch instrument was used to maintain approximate uniformity in 
size and weight of each sample.  The explants were washed in sterile PBS solution 
with 1% penicillin-streptomycin, 2.5ug/ml amphotericin B, and placed in 6-well 
plates within 2 hours of collection, then incubated in Opti-MEM medium 
supplemented with 5% (v/v) FBS, L-ascorbic acid (25 µg/ml), L-glutamine (300 
µg/ml), penicillin (100 units/ml), and streptomycin (100 µg/ml) at 37oC in 5% CO2 
and 95% humidity. Explants were adapted to culture conditions for 24 hours before 
experimental variables were applied. 
Equine synovial fibroblast isolation and culture 
Synovial membrane tissue was collected from normal synovial joints of three 
horses.  Synovial fibroblasts were prepared by a method described in Kojima et al 
(2002). Briefly, tissues were dissociated by mincing and then digested overnight 
with 1 mg/ml type I collagenase (Sigma, St.Louis, MO) in Dulbecco’s modified 
Eagle’s medium (DMEM) in a humidified 5% CO2 incubator at 37oC.  Dissociated 
cells were cultured in 75 cm2 culture flasks in DMEM supplemented with 10% fetal 
bovine serum (FBS), L-glutamine (2mM), 50 U/ml penicillin and 50 µg/ml 
streptomycin.  At greater than 95% confluency, the adherent synovial fibroblasts 
were passaged by digestion with 0.05% trypsin/EDTA.  For all experiments, passage 
4 cells were plated into 6-well plates (0.4x106 cells/well) in DMEM containing 10% 
FBS for 24 h. After seeding, the synovial cells were cultured for an additional 24 h in 
DMEM with 2% FBS and then incubated with or without various experimental 
stimuli.  
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II. Experimental variables in tissue culture 
Pro-inflammatory stimuli with IL-1β and LPS  
To stabilize baseline cell function and levels of gene expression, chondrocyte 
monolayers were cultured for 10 days and synovial fibroblasts for 24 hours prior to 
stimulation.  After the adaptation period, cells were treated with medium containing 
equine recombinant IL-1β (R&D system) (1 ng/ml or 10 ng/ml), or Escherichia coli 
lipopolysaccharide (LPS) (1 ng/ml, 10 ng/ml, or 100 ng/ml) for either 24 hours or 
72 hours.  At the end of the treatment period, the culture medium was collected to 
analyze nitric oxide levels and the cells were lysed for total RNA isolation. 
 
Glucocorticoids 
1. Molecular structures 
Methylprednisolone sodium succinate (MPS) was purchased from Pharmacia-
Upjohn (Kalamazoo, MI). Betamethasone 21-phosphate disodium (BPD) and 
triamcinolone acetonide (TA) were purchased from Sigma (St. Louis, MO). VBP1 was 
synthesized by Bridge Organics (Kalamazoo, MI) (Figure 6). 
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Figure 6. Molecular structures of MPS, BPD, TA and VBP1. 
 
2. Concentrations and solubility 
MPS and BPD were prepared at the initial concentration levels of 10-2 M in 
Opti-MEM.  Serial dilution was performed to reach the target concentrations.  TA 
and VBP1 are both water insoluble compounds.  Stock solutions at a concentration 
of 10 mM were prepared for these two compounds using dimethyl sulfoxide (DMSO; 
Sigma, St.Louis, MO) as a diluent.  Serial dilutions were used to reach target 
experimental concentrations.  The final volume of DMSO in culture medium was 
below 1% (v:v).  
MPS BPD 
TA VBP1 
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3. Evaluation of glucocorticoids administration protocols 
a) Timing of methylprednisolone treatment relative to IL-1β stimulation 
Chondrocyte aggregates and synovial fibroblasts were treated with a dose of 
10-4 M methylprednisolone (Pfizer) with or without 1 ng/ml equine recombinant IL-
1β (R&D system).  Three methylprednisolone (MPS) treatment models: pre-treated 
with MPS (IL-1β 24h; MPS 36h); post-treated with MPS (IL-1β 24h; MPS 12h); 
treated together with MPS and IL-1β (IL-1β 24h; MPS 24h) were tested. 
Chondrocyte aggregates were pre-cultured in Opti-MEM medium without any 
stimulus for 10 days and synovial fibroblasts were pre-cultured in DMEM medium 
without any stimulus for 24 hours to adapt to culture conditions. After pre-culturing, 
cells were re-fed with fresh medium with 1 ng/ml IL-1β or 10-4 M MPS alone, 1 
ng/ml IL-1β and 10-4 M MPS, or fresh medium without any treatment for 12 hours.  
Cell culture medium was changed and cells were re-fed with medium containing 
MPS alone, IL-1β and MPS, or without any treatment for other 12 h. Cells in the MPS 
pre-treatment group were continued culturing in the medium with IL-1β and MPS 
for 12 more hours. Cells and medium in the other two groups were collected for the 
following study. Cells stimulated with IL-1β alone were used as positive controls, 
and cells without any stimulation were used as negative controls for this study. 
b) Anti-inflammatory efficacy  
Methylprednisolone acetate (MPS) from Pfizer, betamethasone 21-phosphate 
disodium (BPD) from Sigma, and triamcinolone acetonide (TA) from Sigma were 
used for this study. VBP1 was donated by Bridge Organics. The following treatment 
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groups were investigated: control treatment with no corticosteroid treatment and 
free of recombinant equine interleukin-1β(IL-1β); control treatment with DMSO 
without corticosteroid treatment and free of IL-1β;IL-1β stimulation containing only 
1ng/ml IL-1β without corticosteroid addition; MPS (10-4 or 10-6 M), BPD (10-4 or 10-
6 M), TA (10-5 or 10-6 M) or VBP1 (10-5 or 10-6 M) only without IL-1β stimulation; MPS 
(10-4 or 10-6 M), BPD (10-4 or 10-6 M), TA (10-5 or 10-6 M) or VBP1 (10-5 or 10-6 M) 
each with 1ng/ml IL-1β added to the medium (Figure 7). The drug concentrations 
were extrapolated from dosages used clinically and the previous cytotoxicity study. 
After incubation with treatment, chondrocytes and spent medium were harvested. 
All medium were stored at -70 oC until analyzed. Before collection, chondrocytes 
were rinsed twice using PBS, scraped from the culture plate, and stored at -70 oC. 
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Figure 7. Timing and sequence of drug treatment and IL-1β stimulation for 
evaluating the anti-inflammatory efficacy of methylprednisolone, betamethasone, 
triamcinolone, and VBP1 treatment on articular chondrocytes. 
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III. RNA isolation 
Total RNA was isolated from chondrocytes and synovial fibroblasts using the 
QIAGEN RNeasy Mini Kit (QIAGEN). After cells were rinsed with D-PBC, total RNA 
was isolated according to manufacturer’s protocol. Total RNA quantity and purity 
were assessed with a NanoDrop ND-1000.  RNA integrity assessments were 
performed with a BioAnalyzer 2100 (Agilent, Eukaryotic Total RNA Nano Series II) 
and were deemed suitable for downstream applications based upon RNA integrity 
number >8, 28S:18S rRNA ratio >1.8, UV 260:280 ratio >1.8, and UV 260:230 ratio 
>1.7. 
IV. Reverse transcription and Real-time qPCR  
Differential expression of nine genes, interleukin-1 β (IL-1β), interleukin-6 (IL-
6), inducible nitric oxide synthase (iNOS), matrix metalloproteinase 3 (MMP3), 
matrix metalloproteinase 9 (MMP9), matrix metalloproteinase 13 (MMP13), tissue 
inhibitor of metalloproteinases 2 (TIMP2), type II collagen (COL2A1) and hyaluronic 
acid synthase 2 (HAS2), was analyzed using quantitative polymerase chain reactions 
(RT-qPCR) (Table 3). Briefly, total RNA was reverse-transcribed into cDNA using an 
oligo-dT primer with the Promega Reverse Transcription System (Promega, cat. no. 
A3500).  Total RNA (0.5 µg) was diluted in 39 µl nuclease-free water, and combined 
with 41 µl reverse transcription master mix: 3 µl (20 U/ µl)avian myeloblastosis 
virus (AMV) reverse transcriptase, 4 µl oligo dT primer (0.5 µg/ µl), 2 µl RNAsin (40 
U/ µl), 8 µl dNTP (10 mM), 8 µl AMV buffer, and 16 µl MgCl2  (25 mM) (Promega, 
Madison, WI), for each reverse transcription reaction. Samples of cDNA were then 
stored at -20 oC until further analyzed. 
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 Quantitative “real-time” PCR (7900HT Fast Real-Time PCR Systems, Applied 
Biosystems, Foster City, CA) was performed using TaqMan Gene Expression Master 
Mix (Applied Biosystems) and intron-spanning primer/probe sets (Assays-by-
Design, Applied Biosystems) designed from equine genomic sequence data 
(Ensembl – http://www.ensembl.org/Equus_caballus/index.html; UCSC Genome 
Browser – http://genome.ucsc.edu).  Equine-specific RPLPO, EIF2B2, TMF1, IL-1β, 
IL-6, iNOS, MMP3, MMP9, MMP13, TIMP2, COL2A1, and HAS2 primer/probe sets 
were designed for this purpose. Given thought to the gene’s stability, efficiency, CT 
range, and CT values compared to target genes, endogenous control genes were 
used on the target gene plates. Large ribosomal protein (RPLPO), eukaryotic 
translation initiation factor 2B (EIF2B2), TATA element modulatory factor (TMF1) 
and hypoxanthine phosphoribosyltransferase (HPRT) were selected as endogenous 
control genes  because they showed the greatest stability for the sample set as 
defined by the geNorm reference gene application (data not shown).  Amplification 
efficiencies were measured by the default fit option of LinRegPCR (LinRegPCR 7.0, J. 
M. Ruijter and C. Ramakers, Academic Medical Center, Amsterdam, the Netherlands) 
while maintaining the cycle threshold as a data point within the measured 
regression line. Mean efficiencies for each gene across the whole experimental 
groups were utilized for data analysis. Relative expression levels of target genes 
were normalized to the relative quantities of endogenous control genes using 
geometric mean with the geNorm VBA applet.  
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Gene Name Gene 
Symbol 
Forward Primer Reverse Primer 
Eukaryotic translation 
initiation factor 2B  
EIF2B2 TCTGTGCTCCTATGTTCAAGCTTT TTCTTCAAGCAGCCACAAACTTGT 
Hypoxanthine 
phosphoribosyltransferase 
HPRT GCTGAGGATTTGGAAAAGGTGTTT CTCCCATCTCCTTCATCACATCTC 
Large ribosomal protein RPLPO CTGATTACACCTTCCCACTTGCT AGCCACAAATGCAGATGGATCA 
TATA element modulatory 
factor  
TMF1 GCGAAGCTGCTGAAAGTCA GCCTCCCTTTTATCCAGTTCTCAT 
Interleukin-1 β   IL-1β CCGACACCAGTGACATGATGA ATCCTCCTCAAAGAACAGGTCATTC 
Interleukin-6  IL-6 GGATGCTTCCAATCTGGGTTCAAT TCCGAAAGACCAGTGGTGATTTT 
Inducible nitric oxide 
synthase  
iNOS GCGTTACTCCACCAACAATGG CCAGATCCGGAAGTCATGCTTTC 
Matrix metalloproteinase 3  MMP3 GCAGAAAACATACTTCTTTGTAGAGGAC
AA 
GATAGCCTGGCTCCATAGATTGT 
Matrix metalloproteinase 9  MMP9 CGCAAGCCGATATCGTCATC CCATCGAAGGGATACCCATCTC 
Matrix metalloproteinase 
13  
MMP13 GAGCATCCTTCCAAAGACCTTATCT GGATAACCTTCCAGAATGTCATAACC
A 
Tissue inhibitor of 
metalloproteinases 2  
TIMP2 CTGGACGTTGGAGGGAAGAAG CCGTTCCCATCGGCCTTT 
Type II collagen  COL2A1 CTGGCTTCAAAGGCGAACAAG GCACCTCTTTTGCCTTCTTCAC 
Hyaluronic acid synthase 2  HAS2 CAGAGCACTGGGACGAAGT CAGGGTCAAGCATGGTATCTGAAT 
 
Table 3. Primer nucleotide sequences used in RT-qPCR assays for genes described in the study
3
6
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V. Nitric oxide production  
For measurement of nitrite in the cell supernatants, chondrocytes and synovial 
fibroblasts were plated into the wells of a 6-well plate at a density of 0.4 x 106 
cells/well in phenol red free Opti-MEM containing 5% FBS or phenol red free DMEM 
containing 2% FBS and incubated for 24 h in the presence or absence of IL-1β, with 
or without treatment. Nitrite concentrations were measured in cell supernatants as 
an indicator of NO production using a commercially available Griess reaction kit 
(Cayman, Ann Arbor, MI, USA). Assay was performed according to the 
manufacturer’s recommendation. 
 
 
VI. Glucocorticoid-induced chondrocyte cytotoxicity 
In vitro analysis 
1. Culture methods 
Primary articular chondrocytes were seeded in 96-well plates at a density of 1 
x 104 cells/cm2. The cultures were maintained in Opti-MEM medium supplemented 
with 5% (v/v) FBS, L-ascorbic acid (25 µg/ml), L-glutamine (300 µg/ml), penicillin 
(100 units/ml), and streptomycin (100 µg/ml), and incubated at 37oC in 5% CO2 and 
95% humidity for 24 hours to adapt to culture conditions. 
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2. Dose-and time-dependent effects of glucocorticoids 
Once adapted to culture conditions, chondrocytes were washed 3 times in D-
PBS solution and placed in fresh Opti-MEM medium (control) or medium containing 
MPS, BPD, or TA in varying concentrations in 96-well plates with 4 replicates. 
Triamcinolone acetonide powder was dissolved in 2-hydroxypropal-β-cyclodextrin 
(HC) (Sigma-Aldrich, St Louis, MO). The percentage of HC in culture media was kept 
at levels no higher than 2%, according to the cytotoxicity assay for HC solution in 
chondrocytes. The concentrations of MPS, BPD and TA included levels routinely 
used in clinical practice (Table 4). Chondrocytes were treated with MPS, BPD, or TA 
for 3, 6, 12, 24 or 72hours. Catilage explants were also treated with previously 
mentioned drug at the same concentration levels for 72 hours.   
  
 
 
 
 
 
 
Table 4. Concentrations of methylprednisolone, betamethasone, and triamcinolone used to evaluate the glucocorticoid-
induced chondrocyte cytotoxicity in chondrocyte cell culture and cartilage explants.   
Drug Concentration (M) 
MPS 2x10-8 2x10-7 2x10-6 2x10-5 2x10-4 4x10-4 6x10-4 1.6x10-3 2x10-3 2x10-2 1x10-1 
BPD 2x10-7 2x10-6 2x10-5 2x10-4 2x10-3 4x10-3 6x10-3 1.2x10-2 4x10-2 1x10-1  
TA 5x10-9 5x10-8 5x10-7 5x10-6 1x10-5 2.3x10-5 5x10-5 9x10-5 2x10-4   
3
9
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3. Assessing cell viability 
a) Chondrocyte monolayer cell culture 
Chondrocytes cytotoxicity assay was performed using the 3-(4,5-
dimethylthiazol-2yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt (MTS) method using a commercially available kit (CellTiter 96 
Aqueous one Solution Cell Proliferation Assay; Promega, Madison, WI, USA) 
according to the manufacturer's instruction. This method has shown to be an 
accurate indicator of cell viability by measuring mitochondrial NADPH or NADH-
dependent dehydrogenase activity. The MTS tetrazolium compound is directly 
reduced by cellular NADH and NADPH to generate a colorimetric reaction. Briefly, 
chondrocyte cells were seeded in 96 well plates at a density of 1 x 104 cells/well and 
cultured in the Opti-MEM with 5% fetal bovine serum.  
 Chondrocyte cell viability was assessed after 3h, 6h, 12h, 24h and 72h 
culturing with methylprednisolone, betamethasone, or triamcinolone respectively. 
The cells were incubated with 20 µl of CellTiter 96 Aqueous one Solution for 3h at 
37°C in a humidified atmosphere of 5% CO2. Plates were read on a microplate 
spectrophotometer at 490 nm. The cells were evaluated regularly for morphological 
changes. Data are expressed as the percentage of viable cells compared to control 
samples. 
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b) Cartilage tissue 
After 24 hours pre-culture, explants were washed 3 times with D-PBS and re-
fed with fresh media containing different concentrations of glucocorticoid drugs. 
After 72 hours treatment, the cell culture medium was removed and explants were 
washed 3 times in D-PBS solution.  
The LIVE/DEAD viability/cytotoxicity kit for mammalian cell from Molecular 
Probe was used to simultaneously detect live and dead cells. It achieves this by 
utilizing two fluorescent labels; calcein-AM is metabolised by living cells to produce 
a green fluorescent substrate, ethidium homodimer enters cells whose membranes 
have been compromised and emits a red fluorescence. Glucocorticoid treated 
explants were incubated individually with 1 ml PBS containing 10 μM calcein-AM 
and 2 μM ethidium homodimer at 37°C for 30 min, and washed again in PBS, 
mounted onto slides and viewed by confocal microscopy. Data are expressed as the 
percentage of viable cells compared to control samples. 
 
In vivo analysis 
1. Animals 
Nine horses at 3-4 years of age were studied (Table 5). All horses had a thorough 
physical, lameness and radiographic examination of their metacarpal-phalangeal 
and metatarsal-phalangeal (fetlock) joints before entry into the study. All horses 
included in the study were free of both clinical and radiographic evidence of 
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osteoarthritis and severe joint lesions. Horses were stabled on treatment days and 
were allowed free exercise in a paddock on non-treatment days. All procedures for 
this study were approved by the Animal Care and Use Committee at University of 
Kentucky. 
Experimental groups Horse ID Gender Age (Y) 
Methylprednisolone 
I-4 M 4 
N-124 F 4 
I-5 M 4 
Betamethasone 
J-4 M 4 
J-7 M 4 
J-11 M 4 
Triamcinolone 
J-14 M 4 
J-16 M 4 
J-17 M 4 
 
Table 5. Horse  ID, gender and age for nine horses in each treatment group. 
 
The nine horses were randomly assigned into the three treatment groups: 
methylprednisolone, betamethasone, or triamcinolone treatment. Each treatment 
group had 3 horses. The same drug was administered to the left front and left hind 
fetlock joint of each horse, with the contra-lateral fetlock (right front, right hind) 
receiving saline. This design results in a total of 6 replicates for each medication 
with a further division of 3 applications per drug in the front fetlock and 3 
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applications of the drug in the rear fetlock (Figure 8).  The same treatment was 
administered a total of two times, separated by an interval of one month.   
 
Figure 8. Experimental design for intra-articular corticosteroid drug treatment in 
nine horses. Each experimental group had 3 horses and each horse received two 
injections with the same drug at 4 weeks interval. The left front and hind fetlock 
joints were received corticosteroid injections, with the contra-lateral fetlocks 
receiving saline. 
   
 
 
2. Medicating joints 
Fetlock joints at the time of injection were aseptically prepared by cleaning the 
area with 70% EthOH and 2% Chlorhexidine using standard aseptic procedures to 
minimize the potential of contaminating bacteria at the injection site.  After 
preparation of the injection site, the appropriate volume of drug or saline was 
injected into the joints.  Intra-articular injections of methylprednisolone, 
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triamcinolone, and betamethasone were administered in the fetlock joint by a 
licensed veterinarian at the upper limit of the treatment range as recommended by 
the manufacturer.  Drug-treated fetlock joints were received either 80 mg/joint of 
methylprednisolone (Depo-Medrol), 12 mg/joint of betamethasone (Celeston), or 9 
mg/joint of triamcinolone (Kenalog) individually (Table 6).  The contra-lateral 
paired joints receiving the same amount of saline were used as controls. 
 
 
 
 
Drug 
(Generic name, 
Trade name) 
Commercial product 
concentration 
Intra-articular  
dose for 
proposed 
experiment 
Volume of 
drug 
(ml/joint) 
Volume of 
amikacin  
(ml/joint) 
Total volume of 
solution injected 
into joint 
(ml/joint) 
Triamcinolone 
acetonide  
 
Kenalog 
10 mg/ml 
 
9 mg/joint 0.9 ml 0.25 0.9 +0.25 + 1.1 ml 
saline =2.25 ml 
Betamethasone 
 
Celeston, Soluspan 
 
3 mg betamethasone 
acetate, 3 mg 
betamethasone sodium 
phosphate, total 6 
mg/ml 
12 mg/joint 2 ml 0.25 2.25 ml 
Methylprednisolone 
acetate 
 
Depo-Medrol 
40 mg/ml 80 mg/joint 2 ml 0.25 2.25 ml 
 
Table 6. Volumes and concentrations of steroid drug solutions injected into horse fetlock joints. 
4
5
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3. Sample collections 
Three days after the second injection, all horses were humanely euthanized 
using commercial sodium pentobarbital euthanasia solution (Beuthanasia D, 
Intervet). All tissue samples were collected postmortem. The fetlock joint was 
dissected free from surrounding skin and subcutaneous tissues and in its entirety 
isolated by transecting the proximal phalangeal and third metatarsal/metacarpal 
bone with a band saw within 1 h after euthanasia.  After opening, the joints were 
inspected visually to exclude macroscopic pathology.  Subsequently, articular 
cartilage plugs were collected perpendicular to the articular surface from 2 
predefined locations on the proximal articular surface of the first phalanx using a 6-
mm diameter biopsy punch to maintain approximated size and weight uniformity of 
each sample (Brama et al. 2009).  One cartilage plug was collected from the dorsal 
edge of the articular surface (site 1, Figure 9a, b). This site is exposed to dynamic, 
intermittent peak-type loading other than the weight bearing during standing or 
moving at slow speed (Figure 9c, Brama et al. 2001). A second cartilage plug was 
harvested from the mid-region of the joint cavity (site 2, Figure 9a, b). This site is 
constantly loaded whenever the limb is weight bearing, but it is not exposed to the 
peak loads and shear forces to which site 1 is exposed (Figure 9c, Brama et al. 2001).  
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Site 1 Site 2Proximal phalanx
c
Normal weight-bearing Hyperextension due to peak 
loading
Site 1
Site 2
Site 1
Site 2
a b
 
Figure 9. Anatomical sampling sites of articular cartilage plugs from the lateral 
proximal articular surface of the proximal phalangeal bone. The articular cartilage 
plugs (diameter 4 mm) were taken the dorsal edge of the articular surface of the 
proximal phalanx (site 1) and the mid-region of the joint cavity (site 2). Site 1 
exposed to dynamic, intermittent peak-type loading other than the weight bearing 
during standing or moving at slow speed. Site 2 is the consistently weight bearing 
position, but experiences lower absolute forces than site 1 (Brama et al. 2001). 
 
 
 
4. Analysis of cell death 
Cell viability within treated and control samples was evaluated immediately 
after sample collections. Two section vertical slices 1 mm thick were cut through 
each articular cartilage sample with a scalpel and incubated in 1 ml PBS containing 2 
μM calcein-AM and 5 μM ethidium homodimer at 37°C for 30 min.  Confocal 
fluorescence imaging (Leica TCS SP5) using 495 nm excitation and separation of 
green (515 nm) and red (635 nm) fluorescence was used to visualize live and dead 
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cells, respectively. A 10 x objective was used and six images (1.5 x 1.5 mm2) were 
combined to obtain one of the entire slice. To quantify cell viability, the images were 
analyzed using Image J (National Institute of Health, Maryland) as described 
previously (Natoli et al. 2008). Percent viability was measured over a square area 
defined by the full thickness of the explants (Figure 10 and 11). 
 
 
4 mm
Superficial layer
Deep zone
Stain with 2µM Calcein AM 
5 µM EthD-1 for 30 min
Visualize using Confocal Microscope
Joint surface of proximal phalanx
Sample trimming to 1 mm thick slice
Articular surface
Tide mark
Calcified cartilage
Subchondral bone
Superficial zone
Middle zone
Deep zone
 
Figure 10. Articular cartilage sample collection, dissection and staining. The 
articular cartilage plugs (diameter 4 mm) were taken perpendicular to the articular 
surface and down to the calcified cartilage from 2 predefined locations on the joint 
surface of the proximal phalanx using 4 mm diameter biopsy punch. Samples were 
trimmed to 1 mm thick slice and incubated in 1 ml PBS containing 2 μM Calcein-AM 
and 5 μM EthD-1. Confocal microscope was used to visualize the live and dead cells. 
Cartilage schematic image was taken from Geistlich Surgery. 
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1.5 mm area for imaging
Begin
End
30 um
10 x objective, 6 sections were imaged,
each imaged area was 5 µm thick
6 images per sample
Live cells with green staining Dead cells with red staining
 
Figure 11. Visualization with Confocal Microscope. The imaging area was 1.5 x 1.5 
mm2. A 10 x objective was used to observe the samples and six images (1.5 x 1.5 
mm2) were combined to obtain one sample. Live cells were stained with green color 
and dead cells were stained with red color. 
VII. Statistical analysis 
The data are expressed as mean +/- sem. Statistical analysis was done using 
one-way analysis of variance followed by Turkey’s multiple comparison procedure. 
P < 0.05 was considered statistically significant. 
Data for in vivo study were analyzed using the General Linear Model procedure 
(GLM procedure) of the SAS software. Each treated or untreated fetlock joint of 
horse was considered as one block. The model included horse, block and their 
interactions as covariates, and a treatment as a primary variable of interest. Data 
were analyzed by use of ANOVA. Significance was defined as values of p-value<0.05. 
Copyright ©  Wenying Zhu 2015 
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Chapter III Results  
I. Establish an in vitro glucocorticoid treatment model 
In order to develop a cell culture model for studying the effects of 
glucocorticoids on primary equine articular chondrocytes, length of pre-culture, 
pro-inflammatory stimuli, and timing of treatments were compared.  
Establish a chondrocyte culture model with stable gene expression pattern. 
Three genes including the housekeeping gene RPLPO were investigated by 
quantitative RT-PCR.  Following normalization to steady state levels RPLPO mRNA, 
time-dependent changes in the expression of MMP3 and MMP9 were evaluated over 
14 days in culture. The relative mean expression levels of each gene were compared 
between chondrocytes prior to seeding (defined as 1.00) and cultured chondrocytes 
at seven time points (days 1, 2, 3, 5, 7, 10, 14). The expression levels genes exhibited 
dramatic changes during the culture period. As shown in Figure 12, MMP3 and 
MMP9 exhibited higher expression levels in the early culture period than those in 
the late culture period. The relatively stable expression of MMP3 was observed after 
5 days culturing (Figure 12). MMP9 had relatively stable expression after 10 days 
culturing (Figure 12). The similar gene expression patterns were observed in both 
aggregate and monolayer cultures for two genes.   
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Figure 12. Changes over time of MMP3 and MMP9 mRNA levels in monolayer  
and aggregate  cultures of primary equine articular chondrocytes. Steady state 
mRNA levels for MMP3 and MMP9 genes were measured using quantitative RT-PCR, 
and normalized to RPLPO. Each value represents the mean+/-SEM with three 
replicates. 
 
 Comparing the effects of IL-1β and LPS stimulation on pro-inflammatory gene 
expression in primary articular chondrocytes and synovial fibroblasts. 
Both IL-1β and LPS have been applied to stimulate the inflammatory response 
in joint tissues in published studies. In order to establish an appropriate model of 
joint inflammation, the expression levels of IL-6 and MMP13 were evaluated in 
primary articular chondrocytes and synovial fibroblasts following IL-1β and LPS 
stimulation (Figure 13). This experiment was used to compare the efficacy of IL-1β 
and LPS on stimulating the inflammatory response in these two cell types.  IL-1β 
and LPS both significantly (p<0.05) stimulated these two gene expressions in 
chondrocytes and synovial fibroblasts after 24 or 72 hours stimulation. IL-1β was 
the more potent of stimulus than LPS, especially for synovial fibroblasts. More than 
100-fold differences were observed between IL-1β and LPS stimulated gene 
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expression levels of IL-6 and MMP13 in synovial fibroblasts. Comparing two 
different concentrations (1ng/ml or 10ng/ml) of IL-1β, no significant difference was 
identified (p>0.05).  
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Figure 13. Changes of IL-6 and MMP13 gene expression in primary articular 
chondrocytes (A) and synovial fibroblasts (B) exposed to different concentrations of 
IL-1β and LPS. Cells were stimulated with recombinant equine IL-1β (1ng/ml or 
10ng/ml) or LPS (1ng/ml, 10ng/ml, or 100ng/ml) for 24       or 72      hours. Steady-
state mRNA levels of IL-6 and MMP13 were measured by RT-qPCR, and normalized 
to the expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT 
and TMF1 for synovial fibroblasts. IL-1β was the more potent of stimulus, but both 
significantly (p<0.05, *) stimulated inflammatory responses in two cell types.  No 
significant difference was identified between two different concentrations of IL-1β. 
Data are expressed as mean+/- SEM of three biological replicates. 
  
A: Articular chondrocytes 
B: Synovial fibroblasts 
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Comparing differential expression of six genes in chondrocyte aggregate and synovial 
fibroblasts culture with three different sequences of methylprednisolone treatment 
relative to IL-1β stimulation. 
In order to study the anti-inflammatory effects of glucocorticoids on joint 
tissues, chondrocyte aggregate and synovial fibroblast inflammatory culture models 
were established. Three methylprednisolone (MPS) treatment models: pre-treated 
with MPS (IL-1β 24h; MPS 36h); post-treated with MPS (IL-1β 24h; MPS 12h); 
treated together with MPS and IL-1β (IL-1β 24h; MPS 24h), were tested in 
chondrocytes and synovial fibroblasts. The relative mean expression levels of each 
gene were compared between cells with methylprednisolone treatment and control 
cells with IL-1β stimulation alone. The three treatment models all significantly 
(p<0.05) inhibited IL-1β, IL-6, iNOS, MMP3, MMP13 gene transcriptions stimulated 
by IL-1β (2- 5-fold, Figure 14). The transcription levels of IL-1β, IL-6, iNOS, MMP3, 
MMP13, COL2A1 (chondrocytes), HAS2(synovial fibroblasts) were also compared 
among these three different treatment models. Significant differences were not 
identified among three models (p>0.05). 
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Figure 14. Effects of timing of glucocorticoid treatment on the expression of marker 
genes related to inflammation and normal cell function in primary articular 
chondrocytes (A) and synovial fibroblasts (B). Three methylprednisolone (MPS) 
treatment models: pre-treated     with MPS (IL-1β 24h; MPS 36h); post-treated      
with MPS (IL-1β 24h; MPS 12h); treated together      with MPS and IL-1β (IL-1β 24h; 
MPS 24h), were tested in chondrocytes (A) and synovial fibroblasts (B).   Steady-
state mRNA levels were measured for each gene by RT-qPCR, and normalized to the 
expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT and 
TMF1 for synovial fibroblasts. The three treatment models all significantly (p<0.05, 
*) inhibited pro-inflammatory gene transcriptions stimulated by IL-1β.  Significant 
differences were not identified between the treatment groups. Data are expressed 
as mean+/- SEM of three biological replicates, with IL-1β      positive control cells 
defined as 1.00. 
 
  
A: Articular chondrocytes B: Synovial fibroblasts 
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II. Dose-dependent effects of glucocorticoids on the expression of pro-
inflammatory genes for synoviocytes and chondrocytes 
Inflammation is central to the pathogenesis of osteoarthritis, responsible for 
both the clinical symptoms and progressive destruction of articular cartilage 
through increased production of cytokines and degradative enzymes such as matrix 
metalloproteinases. Controlling inflammation, therefore, is an important therapeutic 
goal and a major beneficial effect of glucocorticoid administration. 
Pro-inflammatory gene expressions in primary articular chondrocytes and synovial 
fibroblasts with glucocorticoid treatment. 
 To study the effects of glucocorticoids, steady-state mRNA levels of 5 pro-
inflammatory genes were tested using quantitative RT-PCR. As previously reported 
(Richardson et al., 2000), IL-1β increased steady-state mRNA of IL-6, IL-1β, MMP3, 
MMP13 and iNOS dramatically in primary articular chondrocytes and synovial 
fibroblasts. Methylprednisolone(MPS) (10-4M or 10-6M) significantly (p<0.05) 
inhibited IL-6, IL-1β, MMP3, and MMP13 gene expression in both cell types, as well 
as iNOS in chondrocytes, when compared to control cells with IL-1β stimulation 
alone (Figure 15). These decreases ranged over the tested two doses range from 
30% to 80% (Figure 15). Comparing the effects of two different doses of MPS on 
pro-inflammatory gene transcriptions, no significant difference was observed 
between these two concentrations (p>0.05). 
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The similar results were observed in betamethasone (BPD) and triamcinolone 
(TA). BPD (10-4M or 10-6M) significantly suppressed IL-6, IL-1β, MMP3, MMP13 and 
iNOS gene transcriptions in chondrocytes (Figure 16A), IL-1β and MMP13 in 
synovial fibroblasts as well (Figure 16B). However, no significant difference was 
observed between the two BPD concentrations (p>0.05). TA (10-5M or 10-6M) also 
significantly suppressed IL-6, MMP3, MMP13 and iNOS gene transcriptions in 
chondrocytes (Figure 17A), IL-6, IL-1β and iNOS in synovial fibroblasts as well 
(Figure 17B). The same as MPS and BPD, no significant difference was observed 
between the two TA concentrations (p>0.05). 
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Figure 15. Effect of two different concentrations of methylprednisolone (MPS) on 
expression of pro-inflammatory marker genes in primary articular chondrocytes (A) 
and synovial fibroblasts (B) following IL-1β stimulation. Recombinant equine IL-1β 
(1ng/ml) was used as a pro-inflammatory stimulus. Cells were stimulated by IL-1β 
12 hours prior to MPS treatment.  The cells were then refed with medium containing 
both IL-1β and MPS for another 12 hours.  Steady-state mRNA levels for IL-6, IL-1β, 
MMP3, MMP13, and iNOS were measured by RT-qPCR, and normalized to the 
expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT and 
TMF1 for synovial fibroblasts. Anti-inflammatory activities of MPS were evaluated at 
concentration levels of 10-4 M      and 10-6 M      . Cells treated with MPS showed 
significant (p<0.05, *) changes in gene expression compared to control cells with IL-
1β      stimulation alone.  No significant difference was observed between the two 
different MPS concentrations.  Data are expressed as mean+/- SEM of three 
biological replicates, with IL-1β positive control cells defined as 1.00. 
 
  
A: Articular chondrocytes B: Synovial fibroblasts 
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Figure 16. Effect of two different concentrations of betamethasone (BPD) on 
expression of pro-inflammatory marker genes in primary articular chondrocytes (A) 
and synovial fibroblasts (B) following IL-1β stimulation. Recombinant equine IL-1β 
(1ng/ml) was used as a pro-inflammatory stimulus. Cells were stimulated by IL-1β 
12 hours prior to BPD treatment.  The cells were then refed with medium containing 
both IL-1β and BPD for another 12 hours.  Steady-state mRNA levels for IL-6, IL-1β, 
MMP3, MMP13, and iNOS were measured by RT-qPCR, and normalized to the 
expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT and 
TMF1 for synovial fibroblasts. Anti-inflammatory activities of BPD were evaluated at 
concentration levels of 10-4 M      and 10-6 M      . Cells treated with BPD showed 
significant (p<0.05, *) changes in gene expression compared to control cells with IL-
1β      stimulation alone.  No significant difference was observed between the two 
different BPD concentrations.  Data are expressed as mean+/- SEM of three 
biological replicates, with IL-1β positive control cells defined as 1.00. 
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Figure 17. Effect of two different concentrations of triamcinolone (TA) on 
expression of pro-inflammatory biomarker genes in primary articular chondrocytes 
(A) and synovial fibroblasts (B) following IL-1β stimulation. Recombinant equine IL-
1β (1ng/ml) was used as a pro-inflammatory stimulus. Cells were stimulated by IL-
1β 12 hours prior to TA treatment.  The cells were then refed with medium 
containing both IL-1 β and TA for another 12 hours.  Steady-state mRNA levels for 
IL-6, IL-1β, MMP3, MMP13, and iNOS were measured by RT-qPCR, and normalized 
to the expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT 
and TMF1 for synovial fibroblasts. Anti-inflammatory activities of TA were 
evaluated at concentration levels of 10-5 M      and 10-6 M       . Cells treated with TA 
showed significant (p<0.05, *) changes in gene expression compared to control cells 
with IL-1β      stimulation alone.  No significant difference was observed between the 
two different TA concentrations.  Data are expressed as mean+/- SEM of three 
biological replicates, with IL-1β positive control cells defined as 1.00. 
 
 
 
 
 
 
 
 
  
A: Articular chondrocytes B: Synovial fibroblasts 
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Effects of glucocorticoids and VBP1 on five pro-inflammatory gene expressions in 
primary articular chondrocytes and synovial fibroblasts. 
VBP1, a dissociative glucocorticoid, was reported to maintain comparable anti-
inflammatory efficacy to prednisolone with reduced side effects in muscle cells. 
Accordingly, VBP15 shows promise as a potentially safer therapeutic agent for joint 
inflammation.  Steady-state mRNA levels of 5 pro-inflammatory genes (IL-6, IL-1β, 
MMP3, MMP13 and iNOS) were tested using quantitative RT-PCR. MPS, BPD, and TA 
significantly (p<0.05) inhibited mRNA of pro-inflammatory genes in both cell types 
relative to control cells with IL-1β stimulation alone. There was a significant 
(p<0.05) association between different type of glucoocrticoid treatment and 
expression of IL-6, IL-1β, MMP3, and MMP13.  Significant differences were observed 
among MPS, BPD, and TA for IL-6, IL-1β, and MMP3 in chondrocytes (Figure 18A), 
and IL-6, MMP3, and MMP13 in synovial fibroblasts (Figure 18B).  Comparing VBP1 
to three glucocorticoids, anti-inflammatory efficacies of VBP1 were similar to those 
of TA, however, significantly lower than MPS and BPD.    
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Figure 18. Effects of glucocorticoids and VBP1 on expression of pro-inflammatory 
marker genes in primary articular chondrocytes (A) and synovial fibroblasts (B) 
following IL-1β stimulation. Recombinant equine IL-1β (1ng/ml) was used as a pro-
inflammatory stimulus. Cells were stimulated by IL-1β 12 hours prior to drug 
treatment.  The cells were then refed with medium containing both IL-1β and a drug 
for another 12 hours. Steady-state mRNA levels for IL-6, IL-1β, MMP3, MMP13, and 
iNOS were measured by RT-qPCR, and normalized to the expression of reference 
genes HPRT and EIF2B2 for chondrocytes, and HPRT and TMF1 for synovial 
fibroblasts.  Methylprednisolone      (MPS, 10-6 M), betamethasone       (BPD, 10-6 M), 
and triamcinolone       (TA, 10-6 M) significantly (p<0.05，*) inhibited pro-
inflammatory gene expression in both cell types relative to control cells with           
IL-1β       stimulation alone. Significant differences were observed among different 
drug treatment groups for IL-6 and MMP3 in both cell types, IL-1β in chondrocytes, 
and MMP13 in synovial fibroblasts. Comparing VBP1       to three glucocorticoids, 
anti-inflammatory efficacies of VBP1 were similar to those of TA, however, 
significantly lower than MPS and BPD.  Data are expressed as mean+/- SEM of three 
biological replicates, with IL-1β positive control cells defined as 1.00. 
 
A: Articular chondrocytes B: Synovial fibroblasts 
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iNOS gene expression and inducible nitric oxide synthase activity 
Steady-state mRNA level of iNOS was significantly increased by IL-1β 
stimulation (more than 100-fold) in primary articular chondrocytes. The effect of IL-
1β on iNOS gene transcription was significantly (p<0.05) reversed by 
glucoocrticoids (MPS, BPD, and TA) or VBP1 (Figure 19A). VBP1 at the 
concentrations of 10-5M or 10-6M both inhibited iNOS gene transcription, however, 
significant difference was only observed at 10-5M.  
Nitric oxide (NO) production was significantly increased by IL-1β stimulation 
(more than 100-fold). The effect was reversed by increasing doses of glucocorticoids 
and VBP1. Glucocorticoids and VBP1 reduced IL-1β-induced NO production in a 
dose-dependent manner (Figure 19B). BPD and TA significantly (p<0.05) reduced 
NO production more than 30% when concentrations increased above 10-8M. MPS at 
the concentration levels above 10-6M significantly decreased NO production more 
30%. VBP1 also significantly (p<0.05) inhibited NO production when concentration 
was increased to 10-5M.  
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Figure 19. Effects of glucocorticoids and VBP1 on iNOS gene expression and nitric 
oxide production in primary articular chondrocytes. Recombinant equine IL-1β 
(1ng/ml) was used as a pro-inflammatory stimulus. Cells were stimulated by IL-1β 
12 hours prior to drug treatment.  The cells were then refed with medium 
containing both IL-1β and a drug for another 12 hours. Steady-state mRNA for iNOS 
was measured by RT-qPCR, and normalized to the expression of reference genes 
HPRT and EIF2B2. Nitrite in drug treated chondrocytes was assessed at 
concentration levels of methylprednisolone (MPS: 10-4 ， 10-6， 10-8， 10-9，or 10-
10 M), betamethasone (BPD: 10-4 ，10 -6， 10-8， 10-9，or 10-10 M), triamcinolone 
(TA: 10-5  ， 10-6， 10-8， 10-9，or 10-10 M) or VBP1 (10-5 , 10-6,  10-7,  10-8,  or 10-9  
M) by Griess reagents.  (A) Steady state mRNA of iNOS was increased by IL-1β 
stimulation and the effect was significantly (p<0.05, *) reversed by glucocorticoids 
or VBP1 treatment. Data are expressed as mean+/- SEM of three biological 
replicates, with IL-1β positive control cells defined as 1.00. (B) Nitric oxide 
production was increased by IL-1β stimulation. The effect was reversed by 
increasing doses of glucocorticoids and VBP1. Significant differences were observed. 
Data are expressed as mean+/- SEM of three biological replicates. 
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IL-1β Control 
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Type II collagen gene expression in primary articular chondrocytes with 
glucocorticoids treatments. 
Methylprednisolone, betamethasone, triamcinolone are three commonly used 
intra-articular glucocorticoids in horse, yet drug-induced suppression of type II 
collagen synthesis by chondrocytes has been documented. VBP1 as a potential 
therapeutic agent for joint inflammation may have a reduced side effect on type II 
collagen gene transcription. Dose-dependent effects of glucocorticoids and VBP1 on 
the steady-state mRNA level of type II collagen in chondrocytes were tested. 
Methylprednisolone, betamethasone, triamcinolone, and VBP1 all displayed 
numerically lower levels of steady-state COL2A1 mRNA, but not to an extent that 
was significantly different from the control samples (Figure 20). 
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Figure 20. COL2A1 gene expression in primary articular chondrocytes with 
glucoocrticoids or VBP1 treatment. Cells were exposed to four drugs individually at 
a concentration level of methylprednisolone (MPS, 10-4 or 10-6 M), betamethasone 
(BPD, 10-4 or 10-6 M), triamcinolone (TA, 10-5 or 10-6 M) or VBP1 (10-5 or 10-6 M). 
Steady state mRNA for COL2A1 was measured by RT-qPCR, and normalized to the 
expression of reference genes HPRT and EIF2B2. Data are expressed as mean+/- SD 
of three biological replicates, with IL-1β control cells defined as 1.00. 
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HAS2 gene expression in synovial fibroblasts following equine recombinant IL-1β 
stimulation and treatment with glucocorticoids. 
Hyaluronan (HA), which is produced by synovial fibroblasts, is an important 
component of synovial fluid contributing to properties of viscosity and boundary 
lubrication. In order to evaluate the inhibition of glucocorticoids and VBP1 on HA, 
HA transcription in synovial fibroblasts was analyzed. Hyaluronic acid synthase 2 
(HAS2) mRNA levels were significantly (p<0.05) upregulated by stimulation with 1 
ng/ml IL-1β, as compared with untreated controls (Figure 21). Methylprednisolone, 
triamcinolone, and VBP1 all repressed the HAS2 mRNA levels which were induced 
by IL-1β stimulation, and change levels were from 0.7 fold to 0.89 fold (Figure 21). 
However, significant difference between these three drugs treated samples and 
samples with only IL-1β stimulation was not observed. Betamethasone at 
concentration levels of 10-4 M and 10-6 M significantly (p<0.05) down-regulated the 
HAS2 mRNA levels (Figure 21). 
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Figure 21. HAS2 gene expression in synovial fibroblasts following recombinant IL-
1β stimulation and glucocorticoids or VBP1 treatment. Recombinant equine IL-1β 
(1ng/ml) was used as a pro-inflammatory stimulus. Cells were exposed to 4 drugs 
following IL-1β stimulation at a concentration level of methylprednisolone (MPS, 10-
4 or 10-6 M), betamethasone (BPD, 10-4 or 10-6 M), triamcinolone (TA, 10-5 or 10-6 M) 
or VBP1 (10-5 or 10-6 M). Steady state mRNA for HAS2 was measured by RT-qPCR, 
and normalized to the expression of reference genes HPRT and TMF1. Data are 
expressed as mean+/- SD of three biological replicates, with IL-1β positive control 
cells defined as 1.00. 
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III. Glucocorticoid-induced chondrocyte cytotoxicity  
As a potent anti-inflammatory drug for osteoarthritis, glucocorticoids 
effectively reduce expression of matrix metalloproteinases and help in relieving the 
symptoms of joint inflammation.  However, several side effects of glucocorticoids 
including potential cytotoxicity on chondrocytes have been reported.  The purpose 
of this study is to evaluate the chondrocyte cytotoxicity of different doses of the 
three most commonly used corticosteroids with different length of exposure on 
equine primary articular cartilage in vitro. Subsequently, chondrotoxicities of 
manufacture recommended dosage levels of methylprednisolone, betamethasone, 
and triamcinolone are evaluated on normal equine fetlock joints in order to assist 
the clinician when using an evidence-based approach to the use of intra-articular 
corticosteroid medications. 
Methylprednisolone, betamethasone, and triamcinolone induced chondrocyte 
cytotoxicity in monolayer and explants culture. 
Several in vitro studies have demonstrated conflicting results for the effects of 
corticosteroid on chondrocyte cytotoxicity. In these studies, different experimental 
models and corticosteroids were used, and different endpoints were chosen. In 
order to compare the cytotoxic effects of three commonly used glucocorticoids on 
equine articular chondrocytes, the same experimental models were used in our 
study, and several different time points and drug concentrations were evaluated. In 
chondrocyte monolayer cultures, cell viability decreased below 90% in the presence 
of MPS which concentration levels were equal to or higher than 0.8 mg/ml (1.6x10-3 
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M) at three hour time point (Figure 22A).  After six hours of incubation, cell viability 
fell below 90% when MPS concentrations were equal to or higher than 0.2 mg/ml 
(4x10-4 M)  (Figure 22A).  At the highest concentration of 40 mg/ml (8x10-2 M), 
almost all of the chondrocytes were dead after 3 hours incubation (Figure 22A).  
After 12 hours of incubation, almost all of the cells were dead when MPS 
concentrations were equal to or higher than 10 mg/ml (2x10-2 M) (Figure 22A).  Cell 
death and viability in response to corticosteroid treatment in explants was assessed 
by uptake of ethidium homodimer (red) and calcein-AM (green) fluorescent label 
respectively (Figure 23). The cytotoxicity curve for MPS treated chondrocyte 
explants is quite similar to the curve observed for chondrocytes in monolayer 
culture (Figure 22A).  According to these two experiments, MPS concentrations 
higher than 0.1 mg/ml (2x10-4 M) are cytotoxic to chondrocytes in both monolayer 
and explant culture. 
Similar cytotoxicity curves were observed for betamethasone and triamcinolone. 
At the 3 hour time point, cell viability decreased below 90% when BPD 
concentrations were equal to or higher than 6 mg/ml (1.2x10-2 M) (Figure 22B). 
After 6 hours of treatment, cell viability fell below 90% when BPD concentrations 
were equal to or higher than 2 mg/ml (4x10-3 M) (Figure 22B). At the highest 
concentration of 50 mg/ml (1x10-1 M), almost all of the chondrocytes were dead 
after 3 hours incubation (Figure 22B). After 24 hours of incubation, almost all of the 
cells were dead when BPD concentrations were equal to or higher than 20 mg/ml 
(4x10-2 M) (Figure 22B). Chondrocyte cell viability dropped below 90% when TA 
concentration increased to 0.08 mg/ml (1.8x10-4 M) after 24 hours treatment 
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(Figure 22C). The same to the MPS cytotoxicity experiments, the cytotoxicity curves 
for BPD or TA treated chondrocyte explants and monolayer cultures are very similar 
(Figure 22B, C). According to these experiments, BPD concentrations higher than 1 
mg/ml (2x10-3 M)and TA concentrations higher than 0.04 mg/ml (9x10-5 M), are 
cytotoxic to chondrocytes in both monolayer and explants culture. 
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Figure 22. Methylprednisolone (MPS), betamethasone (BPD) and triamcinolone 
(TA) induced chondrocyte cytotoxicity in monolayer and explants culture. Effects of 
MPS, BPD and TA on cell viability were assessed at 5 different cultured time points 
(3h, 6h, 12h, 24h, 72h) by MTS kit for monolayer cells. For explants culture, cell 
viability was assessed at 9 different concentrations by LIVE/DEAD kit at 72h. Data 
are expressed as means +/- S.E.M. (n=3, 4). 
 
Methylprednisolone, betamethasone, and triamcinolone induced chondrocyte 
cytotoxicity in equine fetlock joints. 
Some limitations of in vitro study, however, must be considered. First, 
chondrocytes cultures may not reflect the complex and highly differentiated 
cartilage tissue. Second, the chondrocytes are stored in the media in a static manner 
and diffusion characteristics likely differ in a moving joint. Another limitation is the 
use of constant concentration of drug in vitro as a model of the clinical injection, 
which is not equivalent to the in vivo joint environment and metabolism. Effect of 
glucocorticoids on chondrocte cytotoxicity therefore need to be evaluated in vivo to 
see if drugs at the manufacture recommended dosage level would cause cell death in 
equine joints.  
All experimental procedures were well tolerated by all of the horses and no 
evidence of joint inflammation and lameness was observed following the 
administration of corticosteroids.  
To assess chondrocyte viability, 2μM of Calcein AM and 10 μM of EthD-1 were 
used to stain dead cells (Red) and live cells (green), respectively. To quantify cell 
viability, the outer contour of the articular cartilage section and the area containing 
viable cells were identified manually. Typical confocal microscopy images of cell 
 
74 
 
viability within the articular cartilage layer which were intra-corticosteroid treated 
(Figure 23 A) and untreated control (Figure 23B), are shown in Figure 23.  
 
 
 
Figure 23. LIVE/DEAD labeling of articular cartilage from equine fetlock joints 
treated with 80 mg/joint methylprednisolone (MPS) or saline. Live cells were 
stained green by calcein-AM, whereas dead cells were stained red by ethidium 
homodimer. A. Equine articular cartilage from a left front fetlock joint of a horse 
treated with 80 mg/joint MPS. B. Equine articular cartilage from a right hind fetlock 
joint of the same horse treated with saline. 
 
Methylprednisolone acetate (MPA) caused a significant (P<0.05) reduction in 
chondrocyte viability compared with the control saline injections (Figure 24). The 
average cell death was increased from 12% in controls to 17.4% with 80 mg/joint of 
MPA injections. Biological variation was observed when cell death of MPA treated 
samples was compared to control samples for each horse. Significant differences 
were observed for two horses. The cell death was increased from 11.4% in controls 
to 20.9% with MPA injections in one horse, and from 9.6% in controls to 17.7% with 
MPA injections in another horse. There, however, is no significant (P>0.05) 
difference was observed for the third horse.  
A B 
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Betamethasone containing betamethasone sodium phosphate and 
betamethasone acetate caused a significant (P<0.05) reduction in chondrocyte 
viability compared with the controls with saline injections (Figure 24). The average 
cell death was increased from 13.2% in controls to 18.5% with 12 mg/joint of 
betamethasone injections. Biological variation was observed when cell death of drug 
treated samples was compared to control samples for each horse. Significant 
differences were observed for two horses. The cell death was increased from 15.5% 
in controls to 22.6% with betamethasone injections in one horse, and from 10.3% in 
controls to 19.5% with betamethasone injections in another horse. There, however, 
is no significant (P>0.05) difference was observed for the third horse. 
Triamcinolone acetonide (TA) caused a significant (P<0.05) reduction in 
chondrocyte viability compared with the controls with saline injections (Figure 24). 
The average cell death was increased from 13.1% in controls to 17.1% with 9 
mg/joint of TA injections. Biological variation was observed when cell death of TA 
treated samples was compared to control samples for each horse. Significant 
differences were only observed for one horse. The cell death was increased from 
9.4% in controls to 18.3% with TA injections in one horse. There, however, is no 
significant (P>0.05) difference was observed for the other two horses.  
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Figure 24. Methylprednisolone (MPA), betamethasone (BPD) and triamcinolone 
(TA) induced chondrocyte cytotoxicity in articular cartilage from equine fetlock 
joints.  Intra-articular MPA (80 mg/joint), BPD (12 mg/joint) and TA (9 mg/joint) 
were injected into left front and hind fetlock joints for 3 horses, respectively. The 
contra-lateral fetlocks (right front, right hind) were received saline injection.  Each 
horse was received 2 injections with the same drug. Effect of MPA, BPD and TA on 
cell viability was assessed 3 days after the second injection by LIVE/DEAD kit. 
Significant differences were observed between treated groups and control groups. 
Data are expressed as means ± S.E.M (n= 6). The percentages of cell death in each 
treatment group are expressed as mean ± S.D in the table.   
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Chapter IV Discussion 
I. Establish an in vitro glucocorticoid treatment model 
Tissue culture parameters and protocols were compared to develop a model 
system for studying the effects of glucocorticoids on primary equine articular 
chondrocytes and synovial fibroblasts. Several cell culture methods have been 
developed to investigate chondrocyte and articular cartilage biological properties 
(Adolphe et al., 1992; Tew et al., 2008). Although nonadherent aggregates and pellet 
culture improve the maintenance of chondrocyte phenotype, they slow the cell 
growth, yielding lower amounts of cells and RNA for analysis. Alternatively, articular 
cartilage can be studied as explant cultures, in which chondrocytes remain 
embedded within their own extracellular matrix (Poole et al., 1989). However, many 
experimental manipulations are done more easily using isolated chondrocytes 
maintained as adherent monolayer cultures (Otero et al., 2012). After considering 
these factors and culturing logistics, monolayer cultures were selected for 
subsequent experiments in this study.   
Length of culture, pro-inflammatory stimuli, and timing of treatments were 
compared. The expression patterns of matrix proteases, protease inhibitors, and 
cytokines in equine articular chondrocytes were evaluated during a 14 day culture 
period to find out when steady state levels of mRNA for target genes of interest 
stabilized. This initial culture period prior to introducing an experimental variable 
was used to minimize error introduced by the effects of chondrocyte isolation and 
cell plating. PCR analysis showed that the expression of all genes of interest was 
markedly and differentially affected by tissue digestion, with differences up to 10 to 
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15 fold (Martin et al., 2001). Consistent with previous reports (Lin et al., 2008), the 
expression of matrix proteinases MMP3 and MMP9 decreased with increasing 
culturing period (Figure 12). Our results also indicated that the expression of MMP3 
became relatively stable after 5 days in culture, and the expression of MMP9 became 
relatively stable after 10 days in culture. Based on these preliminary data, the pre-
culture period for chondrocytes was determined to be 10 days before starting the 
treatment or stimulation, to  allow cells to adapt to the culture conditions and 
eliminate the effects of tissue collection and cell isolation. 
Inflammatory cytokines such as Interleukin-1 (IL-1) β and tumor necrosis 
factor-α (TNF-α) play pre-eminent roles in joint destruction.  In joint diseases, IL-1β 
is synthesized by synoviocytes and cartilage chondrocytes (Martel-Pelletier et al., 
1999; Tiku et al., 1992). IL-1β has been commonly used in articular cartilage and 
synovial membranes for creation of a joint inflammation model.  It has been shown 
to be increased in inflammatory conditions and stimulate the production of matrix 
degradation enzymes such as matrix metalloproteinase (MMP) (Pelletier et al., 
1993). Lipopolysaccharide (LPS) has similar effects to IL-1β on chondrocyte-
mediated matrix metabolism and is, therefore, a useful experimental inducer of 
chondrocyte-generated pathology (Jasin et al., 1983; MacDonald et al., 1994). In 
order to establish a joint inflammation model in vitro, our experiments investigated 
the changes in pro-inflammatory gene expressions in response to LPS or IL-1β in 
chondrocytes and synovial fibroblasts. Similar to previous studies (Jasin et al., 1983; 
MacDonald et al., 1994; Pelletier et al., 1993), both IL-1β and LPS were able to 
significantly stimulate the inflammatory response in articular chondrocytes and 
 
79 
 
synovial fibroblasts. IL-1β was more potent than LPS, especially in synovial 
fibroblasts. However, no significant difference was identified between 1 ng/ml and 
10 ng/ml of IL-1β. IL-1β with 1 ng/ml was used to stimulate the inflammatory 
response in chondrocytes and synovial fibroblasts for subsequent studies. 
Several different in vitro glucocorticoid treatment models were established in 
previous studies: pre-treated with glucocorticoids, then started the inflammatory 
stimulation (Baundy et al., 2009; 2012; Crofford et al., 2004); stimulated the 
inflammatory response first, then post-treated with glucocorticoids (Bertone et al., 
2008; Lu et al., 2011); treated together with glucoocrticoids and pro-inflammatory 
mediators (Frisbie et al., 2001; Busscher et al., 2010; Richardson and Dodge, 2003). 
Three different glucocorticoid treatment models were compared in our studies. The 
length of IL-1β stimulation was controlled to 24 hours. The expression of cytokines, 
matrix proteinases and matrix proteins in chondrocytes and synovial fibroblasts 
was determined by quantitative real-time PCR. All three models repressed pro-
inflammatory gene expressions induced by IL-1β stimulation, and the expression of 
COL2A1 was inhibited in pre-treatment and simultaneous treatment models, not in 
post-treatment model. However, significant differences were not identified among 
these three models. Previous studies by Lin et al. 2011, also demonstrated that 
treating cartilage with glucocorticoids either before or after inflammatory 
stimulation significantly reduced glycosaminoglycans (GAG) loss and increased 
proteoglycan biosynthesis. It suggested that even when catabolic processes have 
already begun in cartilage, glucocorticoid treatment could still suppress GAG loss 
and increase biosynthesis. In clinical cases, patients experience joint pain and joint 
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swelling, and then clinicians treat the inflammatory joints using anti-inflammatory 
medicine. The chondrocytes and synovial fibroblasts used in this study were 
isolated from the normal joints without any sign of joint disease. Therefore, these 
cells may have different biological properties from cells from inflamed joints in 
which inflammatory response has already been initiated.  
Based on these preliminary data and clinical cases, the glucocorticoid treatment 
models in primary equine chondrocytes and synovial fibroblasts were established. 
Primary equine chondrocytes were pre-cultured in cell culturing medium without 
passaging for 10 days. After that, IL-1β at 1 ng/ml was used to initiate the 
inflammatory response in both cell types. Twelve hours later, cells were treated 
with glucoocrticoids in addition to continued stimulation with IL-1β for another 12 
hours. The following experiments were performed using this drug treatment model. 
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II. Dose-dependent effects of glucocorticoids on the expression of pro-
inflammatory genes in chondrocytes and synoviocytes. 
A major finding of this study was that glucocorticoids can maximally inhibit 
pro-inflammatory gene transcriptions in both equine articular chondrocytes and 
synovial fibroblasts at lower doses than widely used clinical dosages.  
The hallmark of osteoarthritis is loss of articular cartilage structure integrity 
and function. In the early stage of disease, multiple structural proteins of the matrix 
are actually increased (MacLeod et al., 1998), however, the net outcome is 
progressive loss of matrix integrity. The elements which play the most important 
role in the degradation of the cartilage matrix are the matrix metalloproteinases 
(MMP). Although there are obvious similarities among the MMPs, each MMP has a 
preferred substrate that presumably is related to its role in development, normal 
tissue remodeling, as well as disease processes. MMP3 (stromelysin 1) is well 
characterized in horse cartilage and believed to have the proteoglycans as preferred 
substrates (Morris et al., 1994; Richardson et al., 1998; Balkman et al., 1998). 
MMP13 (collagenase 3) has type II collagen as a preferred substrate and has been 
studied in equine chondrocytes (Caron et al. 1996; Richardson et al., 2000). It is 
generally accepted that MMP increases in arthritis and that it specifically increases 
in response to many cytokines, which is clear from our results (Figure 15) and those 
of others (Richardson and Dodge, 2003; Pelletier et al., 1993, 1994).  
While the role of NO in the physiology and pathobiology of equine vascular 
reactivity has been the subject of recent research, its role in equine OA pathogenesis 
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has received little study. Results of subsequent short-term experiments using IL-1β 
stimulated cultures complement previous reports describing NO synthesis by 
equine chondrocytes in response to stimulation with proinflammatory mediators 
(Frean et al., 1997; Bird et al., 1997).  Our results indicated that methylprednisolone, 
betamethasone, and triamcinolone attenuated IL-1β induced NO release by primary 
equine articular chondrocytes in a dose-dependent manner. It was also confirmed 
by our results that IL-1β induced NO release by equine chondrocytes correlates with 
a direct stimulation of iNOS gene expression (Figure 19). Real-time qPCR results 
indicated that expression of iNOS in chondrocyte was inhibited by all of three 
glucocorticoids at 10−6M. In other species, a number of isoforms of NOS have been 
described and vary in their sensitivity to glucocorticoids (Caron et al., 1993; Tung et 
al., 2002). Many iNOS isolated from mammalian chondrocytes are insensitive to 
corticosteroids at modest doses, however, paralleling our findings, equine iNOS 
expression is inhibited with high doses of methylprednisolone, betamethasone, and 
triamcinolone. These findings may suggest a limited influence of endogenous 
glucocorticoids on iNOS expression but that pharmacologic doses are inhibitory. 
Glucocorticoids clearly have complex effects on many genes which are 
important in the synthesis and maintenance of articular cartilage. The mechanism of 
corticosteroid inhibition of matrix metalloproteinase and cytokines synthesis is 
probably related to the inhibition of NF-κB-regulated pro-inflammatory transcripts 
(Richardson and Dodge, 2003). Because the effects of glucocorticoids on matrix-
related genes are dose-dependent, specific to certain genes and occur through 
various mechanisms, it appears that beneficial effects of steroids may be obtained at 
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doses that do not adversely affect matrix protein synthesis. The independent 
mechanisms also offer the future possibility of independently regulating these genes. 
Although it is impossible to directly relate synovial fluid concentrations of 
glucocorticoids with those actually affecting the chondrocytes within articular 
cartilage, the molar concentrations were approximately 10-3 M to 10-5 M following 
intra-articular injection of 100 mg of the steroid. This corresponds to the range of 
concentrations studied in our experiments. Although concentrations of 
glucocorticoids that we studied in vitro were close to the range of expected tissue 
concentrations seen in vivo, the actual concentrations exposed to the chondrocytes 
are not known. It also must be acknowledged that the complexity of glucocorticoid 
effects on other cells in the joint may be important in the net therapeutic result. 
Dose-dependent effects of glucocorticoids and VBP1 on the steady-state mRNA 
level of COL2A1 in chondrocytes and HAS2 in synovial fibroblasts were tested. The 
same as the previous studies (Tanimoto et al., 2001; 2010), HAS2 gene expression 
was significantly up-regulated by IL-1β stimulation. From the Figure 20, it can be 
seen that glucocorticoid treatments suppressed the gene expression of type II 
collagen, however, significant differences were not detected (P<0.05). Suppression 
of steady-state gene expression of type II collagen wasn’t expected as we 
hypothesized. The data was consistent with our previous studies (Figure 14A). In 
our drug treatment model comparison experiments, steady-state mRNA level of 
type II collagen was only significantly decreased in models with 24h or 36h 
methylprednisolone treatment, not in the model with 12h drug treatment (Figure 
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14A). One of the reasons is that cells were not treated with glucocorticoids long 
enough to see the inhibition of steady-state level of type II collagen mRNA. 
Degradation of mRNA is one of the key processes that control the steady-state level 
of gene expression. In general, mRNA species with a short half-life were enriched 
among genes with regulatory functions, whereas mRNA species with a long half-life 
were enriched among genes related to metabolism and structure (extracellular 
matrix, cytoskeleton) (Sharova et al., 2009). The mRNA half-life for type II collagen 
is about 17 hours in rabbit articular chondrocytes and 18 hours in human costal 
chondrocytes (Galera et al., 1992; Goldring et al., 1994; Mark et al., 2004). In this 
study, chondrocytes were treated with glucocorticoids for 12 hours, therefore, the 
level of type II collagen mRNA was still elevated upon withdrawal of drug treatment. 
Our results verified the former studies that type II collagen mRNA, as an important 
extracellular matrix protein gene in chondrocytes, has a relatively long half-life 
which is longer than 12 hours in equine articular chondrocytes. In this study, 
steady-state mRNA of type II collagen was evaluated, however, significant 
differences might be detected between control cells and glucocorticoid treated cells 
if only newly synthesized type II collagen mRNA were evaluated. 
From what we observed, some further experiments could be planned for future 
studies.  One of the experiments which could be done is using the same drug 
treatment model to analyze newly synthesized type II collagen mRNA to see if 
glucocorticoids would suppress type II collagen mRNA synthesis or not.  The effect 
of glucocorticoids on gene expression levels of some other biomarker genes 
(aggrecan, type I collagen, link protein) for articular cartilage also could be 
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evaluated to see if glucocorticoids alter the differentiated phenotype of articular 
chondrocytes or stimulate dedifferentiation into fibroblasts. The other drug 
treatment model also could be tested in the future studies. In the previous reports, 
chondrocytes were treated with medium containing glucocorticoids for at least 24 h 
(Fubini et al., 2001; Richardson and Dodge, 2003; Busschers et al., 2010) prior to 
harvesting cells. The length of drug treatment could be extended. Chondrocytes 
could be cultured in medium containing glucocorticoids for 24, 48, or 72 hours. 
After that, cells could be collected and the effect of glucocorticoids on steady-state 
type II collagen mRNA could be evaluated. Then results also could be compared to 
12 hour results to see if there is any difference between these two drug treatment 
models. 
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III. Glucocorticoid-induced chondrocyte cytotoxicity 
The comparison of effects of methylprednisolone, betamethasone, and 
triancinolone on equine articular cartilage was conducted in this study. The drug 
concentrations used in this study were at the high end of the manufacturer 
recommended doses for equine joint injection, which were commonly used by 
veterinarians according to a survey paper published by Ferris et al. 2011. Taken 
together, all these three corticosteroids have dose-dependent cytotoxic effects on 
equine articular chondrocytes in vitro. Manufacturer recommended concentration 
levels of these three commonly used intra-articular corticosteroids in equine 
practice have cytotoxic effects on equine articular chondrocyte in vivo. The results of 
both our in vitro and in vivo studies are consistent (Table 7).  
Corticoidsteroid  Clinical 
dose 
(mg) 
In vivo 
Cytotoxicity 
conc.(mg/joint) 
In vitro 
Cytotoxicity 
conc.(mg/ml) 
Duration of 
action 
Methylprednisolon
e  
40-120 80 0.2 Medium 
Betamethasone  3-18 12 2 Medium to 
long 
Triamcinolone  6 -18  9 0.08 Long 
 
Table 7. Concentrations of glucocorticoids which have cytotoxicity in vitro and in 
vivo, as well as commonly used corticosteroid concentrations for horse OA 
treatment. 
 
Corticosteroid medications are often injected into the joint space to decrease 
joint inflammation. Even though there is evidence that these medications effectively 
reduce patient symptoms (Blyth et al., 1994; Cole et al., 2005; Pelletier et al., 1994), 
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little is known with regard to their potential cytotoxicity on chondrocytes. 
Concentration-dependent cytotoxicity of methylprednisolone on chondrocytes 
monolayer cultures was observed by Fubini et al. 2009 and Seshadri et al. 2009, and 
these results were consistent with our studies. A recent investigation by Dragoo et 
al. 2012, examined the effect of a single dose of betamethasone, methylprednisolone, 
and triamcinolone on monolayer cultures of human chondrocytes. The authors 
found betamethasone to be significantly cytotoxic to chondrocytes when compared 
with controls (Dragoo et al., 2012). The same results were also observed in both our 
in vitro and in vivo studies. The cytotoxic effects of methylprednisolone and 
triamcinolone on chondrocytes were not reported in Dragoo’s study. However, 
several studies, including our investigations, have also shown detrimental effects of 
triamcinolone on chondrocyte viability (Celeste et al., 2005; Choi et al., 2005; Syed et 
al., 2011). It is reported by Syed et al. 2011 that triamcinolone alone or combination 
with bupivacaine was cytotoxic to chondrocytes when compared with controls. 
These results partially corroborate our findings, however, some in vivo studies 
demonstrated that triamcinolone may not have detrimental effects in patients with 
osteoarthritis (Pelletier et al. 1995) and may actually contribute to histopathological 
improvements in a canine model of osteoarthritis (Raynauld et al., 2003). The 
conflicting results observed in this study coupled with the published reports 
indicate that a cautious clinical approach may be best when evaluating indications 
for the use of triamcinolone and methylprednisolone for intra-articular injections. 
Our study represents a direct assessment of chondrocyte viability after defined 
exposure to three corticosteroids individually using quantitative evaluations. The 
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major advantage of this study was that chondrocyte viability was evaluated in both 
in vitro and in vivo. Multiple drug concentrations and different drug treatment 
points can be tested in chondrocyte cell cultures. Animal models precisely maintain 
the in vivo condition of chondrocytes within articular cartilage bathed in synovial 
fluid, physical pH, and drug diffusion in joint spaces. Some other advantages of this 
study protocol include contra-lateral control and consistency over experimental 
conditions and direct quantitative measurements of chondrocyte viability using 
fluorescent staining. Cytotoxicity of methylprednisolone on equine articular 
cartilage in vivo was reported by Chunekamrai et al. according to the histological 
staining results (Chunekamrai et al. 1989). The concentration of 
methylprednisolone (120 mg/joint) used in that study, however, was higher than 
the commonly used clinical dosage, and  the appearance of empty lacunae at the 
histological level may not be directly related to the effect of the corticosteroid. In 
our study, two florescent dyes were used to visualize the dead and live cells (Figure 
11), and the percentages of cell death were quantified using Image J.   
Variability was observed in our study. Chondrocyte cell death was also 
observed in our control samples with only saline and antibiotic injections. The 
average chondrocyte viability of controls in all treatment groups was about 87% 
which is lower than that in the explants without any injections (Table 8).  Since 
same tissue collection, dissection, and staining processes were performed for 
explants and equine fetlock cartilage samples, the increased cell death in equine 
fetlock cartilage without any corticosteroid treatment may have been caused by the 
injection process and/or combined antibiotic injections. However, chondrocyte 
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viability at 84% for control samples cultured in saline solution was reported in a 
published study (Seshadri et al., 2009). This level is lower than the chondrocyte 
viability in our control samples. In future studies, chondrocyte viability needs to be 
tested in joints without any injection and with only saline treatment.  
Treatment arms Experimental group Viability (%) 
Normal saline 
injection 
Control samples in 
methylprednisolone group 
88% 
Control samples in 
betamethasone group 
87% 
Control samples in 
triamcinolone group 
87% 
Non-injection Explants plug 93% 
 
Table 8. Percentage of live chondrocytes in parallel control joints with normal saline 
injection and in methylprednisolone, betamethasone, or triamcinolone treatment 
groups, and in explants control sample without any treatment.   
 
The potential for artifacts introduced during tissue processing also need to be 
considered. Cut edges were avoided during the imaging of stained articular cartilage 
samples (Figure 4). Dead cells were observed along the cut surface of the deep zone 
of cartilage, and they were consistent in control and treated sample. Chondrocyte 
viability for tissues from the superfacial layer down to the calcified cartilage was 
compared to a subsection of each sample limited to 75% of the cartilage that 
eliminated the cut surface of the deep zone. Correlation analysis was conducted for 
each treatment group. Dead cells in full thickness samples were well correlated to 
those in 75% of cartilage tissues. The correlation coefficients for 
methylprednisolone, betamethasone, and triamcinolone are 0.85, 0.90 and 0.96, 
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respectively (Figure 25).  Statistical analysis was also performed using student t-test, 
demonstrating no significant difference (P>0.05).  
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Figure 25. Correlation analysis of dead cells in full thickness equine cartilage 
samples and those in 75% of cartilage sampls. A. Methylprednisolone treated equine 
fetlock joints. B. Betamethasone treated equine fetlock joints. C. Triamcinolone 
treated equine fetlock joints. 
 
 
 
Limitations of this study include the small number of biological replicates. 
Three biological replicates with paired comparisons were used for in vivo 
experiments in this study. Obviously, biological variation was observed for all of the 
treatment groups (Figure 24). By including more biological replicates for each 
treatment group, more statistical power would be achieved. Another limitation is 
that the cytotoxicity of corticosteroids on chondrocyte was tested in healthy equine 
fetlock joints rather than inflamed joints that would be selected for treatment in 
clinical situations. Effusion and changes in drug pharmokinetics in inflamed joints 
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might alter the results. Further studies, therefore, may need to be conducted to 
evaluate the cytotoxicity of corticosteroid on inflamed chondrocytes. 
Taken together, this study clearly shows a decrease in chondrocyte viability 
after exposure to corticosteroid treatments both in vitro and in vivo. The critical 
finding from this study is that the manufacture’s recommended dose of 
methylprednisolone, betamethasone, and triamcinolone can cause cell death and are 
cytotoxic to chondrocytes. As such, the data support using the lowest concentration 
of corticosteroids possible to achieve desired clinical goals.  
 
Copyright ©  Wenying Zhu 2015 
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Chapter V Conclusion 
I. Reflections 
Research efforts in this dissertation thesis were aimed at examining important 
questions related to the chondrocyte cytotoxicity and anti-inflammatory efficacy of 
glucocorticoids used in the treatment of equine synovial joint inflammation.  The 
primary hypothesis of this work was that manufacture’s recommended dose of 
glucocorticoids currently used in equine clinical practice exceed the amount 
necessary to achieve maximal anti-inflammatory efficacy. In addition, these levels 
are cytotoxic to articular chondrocytes. To test this hypothesis, experiments were 
designed to characterize changes in steady state mRNA for targeted gene transcripts 
in chondrocytes with glucocorticoid treatments and to evaluate drug-induced 
cytotoxicity both in vitro and in vivo.  Within this dissertation results have been 
reported for experiments that have been performed to meet the following two 
objectives: 1) compare the dose-dependent anti-inflammatory profiles of MPS, BPD, 
and TA in synoviocytes and chondrocytes, 2) evaluate glucocorticoid-induced 
chondrocyte cytotoxicity in chondrocytes, articular cartilage explants and equine 
fetlock joints. By focusing on these objectives, the goal is to generate scientific data 
to provide a reference for administrating intra-articular glucocorticoid injections in 
equine practice.   
Intra-articular glucocorticoid injections are commonly used to treat synovitis 
and OA in horses. Since side effects of glucocorticoid on articular cartilage and 
underlying bone have been reported, detrimental side effects remain a major 
concern among the equine practitioners.   These side effects are drug- and dose-
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dependent, so research is needed to define whether the manufacture’s 
recommended dose of glucocorticoids are above a therapeutic optimum in terms of 
relative anti-inflamamtory efficacy and chondrocyte cytotoxicity.  We described the 
first study to examine the three glucocorticoids (MPS, BPD, and TA) induced equine 
articular chondrocytes cytotoxicity both in vitro and in vivo.  Live/Dead assay was 
used to evaluate the chondrocyte cytotoxicity. The results from in vitro and in vivo 
studies were consistent. Dose-dependent effects of glucocorticoids on chondrocyte 
cell death were observed in chondrocyte monolayer culture and cartilage explants. 
With the increase of concentration of glucocorticoids at ranges commonly used in 
equine practice, the percentage of chondrocyte cell death increased.  This study 
supported the hypothesis that manufacture recommended dosage of MPS, BPD, and 
TA can cause chondrocyte cell death.  According to the results from our study 
testing the anti-inflammatory efficacy of glucocorticoids, glucocorticoids were able 
to maintain the full functional efficacy at the low concentration levels. Since the 
survival of articular chondrocytes is essential to maintain cartilage function, the 
data support using the lowest concentration of corticosteroids possible to achieve 
desired clinical goals.   
II. Looking ahead to future studies 
Follow-up studies to those described in the dissertation should focus on two 
areas: 1) determination of effects of glucocorticoids on the expression of biomarkers 
for articular chondrocytes. 2) evaluation of effects of dissociative glucocorticoids on 
pro-inflammatory gene and type II collagen gene expression in articular 
chondrocytes.  
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Effects of glucocorticoids on the expression of biomarkers for articular chondrocyte 
Dose-dependent effects of glucocorticoids on the steady-state mRNA level of 
type II collagen in chondrocytes were tested. It has shown that glucocorticoid 
treatments suppressed the gene expression of type II collagen, however, significant 
differences were not detected (P<0.05).  
From what has been observed, further research on chondrocyte cell biology is 
needed.  Since both detrimental (Dahlberg et.al., 2000; Dechant et al., 2003; Sandler 
et al., 2004) and chondroprotective (Pelletier et al., 1989; Williams et al., 1985) roles 
of glucocorticoids for cartilage have been reported, it would be interesting to detect 
the effects of glucocorticoids on articular cartilage by measuring newly synthesized 
mRNA of cartilage biomarkers. Type II collagen is the principle collagen of articular 
cartilage and plays an essential role in maintaining cartilage architecture and 
biomechanical performance. Aggrecan is the major proteoglycan in the articular 
cartilage and interacts with hylauronan and link protein to endow the cartilage with 
load-bearing properties.  Link protein is also essential for normal biomechanical 
function of articular cartilage. It can attach the aggrecan to hyaluronan thus forming 
the supermolecular aggregate. In the light of their important role in articular 
cartilage, it is important to understand how glucocorticoids affect transcription of 
cartilage biomarkers, such as with nuclear run-on assay. 
 Nuclear run-on is used to measure the transcriptional activity of specific genes 
in intact nuclei (Bates et al., 2002; Laufs et al., 1999). It provides information on the 
synthesis of a specific gene, other than a change in mRNA degradation, transport 
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from the nucleus to the cytoplasm, or steady state mRNA (Figure 26). The same drug 
treatment model in this study, therefore, can be used to analyze effects of three 
glucocorticoids on newly synthesized mRNA of type II collagen, aggrecan core 
protein and link protein. The first step of the nuclear run-on assay is the isolation of 
intact nuclei of treated cells. And then the nuclei are incubated with four 
ribonucleotide triphosphates including radialabelled UTP. This allows the 
transcription of a labeled total mRNA over a defined time in vitro. After that, the 
radiolabeled RNA is isolated and hybridized with appropriate DNA sequences 
immobilized on a membrane (Figure 26). The DNAs usually include the sequences of 
target genes and of an endogenous control gene as a standard. The amount of 
specifically hybridized RNA proportional to the standard and therefore reflects the 
transcriptional activity of genes in the intact cell.  
Isolate nuclei
Gene B
Gene A
Not being transcribed
Actively transcribed
Allow to “run-on” 
in presence of 
radio-labeled 
nucleotides
Gene A
Gene B
Hybridize to specific 
probes
 
Figure 26. Schematic diagram of the process of nuclear run-on.   
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Effects of dissociative glucocorticoids on pro-inflammatory gene and type II collagen 
gene expression in articular chondrocytes 
One of the dissociative glucocorticoids, VBP1, has been tested in this study. 
VBP1 significantly inhibited the iNOS gene transcription and NO production. 
However, the suppression effects of VBP1 on several pro-inflammatory gene 
transcriptions in articular chondrocytes were not significant. There remain some 
questions to the mechanism of action of the VBP compounds on chondrocytes. 
 VBP1 is one of Lazaroid ∆-9,11 analogs and is a water-insoluble compound 
with poor solubility in organic solvent.  It is also reported recently that VBP1 can 
bind to both glucocorticoid receptor and mineralocorticoid receptor with relatively 
high affinity (Reeves et al. 2013). Another dissociative glucocorticoid, VBP15 which 
is a lead compound of the ∆-9,11 steroids, has been reported to inhibit the 
production of NFκB-regulated pro-inflammatory transcripts in human 
macrophages (Dillingham et al. 2015), bronchial epithelial cells (Damsker et al. 
2013), and skeletal muscle cells (Heier et al. 2013).   VBP15 showed greater affinity 
for the glucocorticoid receptor and lower affinity for mineralocorticoid receptor 
than other ∆-9,11 steroids (Heier et al. 2013), indicating that VBP15 has the 
possibility to be a potential candidate for OA therapy. Although VBP15 is also a 
water-insoluble compound, it has better solubility than VBP1 and can be solved in 
8% DMSO + 8% Ethanol + 50% PEG400 + 34% HP-β-CD (20% W/V) (Reeves et al. 
2013), which makes VBP15 as a better candidate that can be tested than VBP1.  
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Since anti-inflammatory efficacy of VBP15 has been reported in several cell 
types, it would be interesting to address the effect of VBP15 on NF-κB-regulated 
pro-inflammatory transcripts in chondrocytes. Chondrocytes can be transfected 
with NF-κB luciferase reporter plasmids (Rockel et al. 2008, Feng et al. 2003). Cells 
expressing NF-κB luciferase reporter will be cultured for the luciferase assay. Drug 
treatment model in the published study (Baudy et al. 2009) will be adopted. Cells 
will be treated with VBP15 at the concentration level of 10-5 M for 24 hours. After 
that, TNF-α at the concentration level of 10ng/ml will be used to induce the NF-κB 
transcription and cells will be treated with TNF-α for 24 hours. Commercially 
available C2C12 cells that expressing NF-κB response elements coupled to 
luciferase in which VBP15 inhibit the NF-κB luciferase activity (Baudy et al. 2009) 
will be used as a positive control. Cells with only TNF-α treatment will be used as a 
negative control. Luciferase values will be normalized as a percentage of TNF-α 
treated only group. This study could be used to determine if VBP15 can inhibit the 
NF-κB transcription in chondrocytes and chondrocytes are refractory to VBP15.  
Additionally, effects of VBP15 on pro-inflammatory and chondrocyte biomark 
genes transcription can be evaluated as well. To confirm effects of VBP15 on NF-κB 
target genes in chondrocytes, several inflammatory transcripts such as IL-1β, IL-6, 
Cox2, iNOS, MMP3, and MMP13 can be assayed by Real-time qPCR in VBP15 and 
MPS treated chondrocytes. One of the reported detrimental effects of 
glucocorticoids on articular cartilage is that glucocorticoids suppressed the 
transcription of type II collage. In order to evaluate the detrimental effects of 
VBP15 on articular cartilage, type II collage transcription can be analyzed in VBP15 
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treated chondrocytes. Inhibition effects of VBP15 on type II collage transcription in 
chondrocytes will be compared to those of MPS treated groups.  
Glucocorticoids are important drugs in joint inflammation therapy. Although 
they have strong anti-inflammatory efficacy, several detrimental side effects are 
identified. Most of anti-inflammatory effects are mediated by transrepression, 
while many side effects are due to transactivation. Dissociative glucocorticoids, 
such as VBP15, can induce transrepression with little or no transactivation activity. 
Accordingly, dissociative glucocorticoids may be potential agents for joint 
inflammation therapy. This study may be able to provide molecular insight into the 
molecular mode of dissociative glucocorticoids activities in joint tissues.  
 
Copyright ©  Wenying Zhu 2015 
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